var title_f16_35_16944="Mechanisms Mahaim tachy";
var content_f16_35_16944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanisms for a Mahaim fiber tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 172px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The typical Mahaim fiber tachycardia circuit involves the Mahaim fiber as the antegrade limb and the atrioventricular (AV) node/His Purkinje system as the retrograde limb (panel C). Alternatively, there may be a second accessory AV pathway which serves as the retrograde limb (panel A). A wide QRS complex tachycardia, resembling a Mahaim fiber tachycardia, can occur when a Mahaim fiber acts as a bystander pathway, conducting antegradely, during an atrioventricular nodal reentrant tachycardia (panel B). The red arrow indicate the direction of impulse conduction within the circuit.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16944=[""].join("\n");
var outline_f16_35_16944=null;
var title_f16_35_16945="Antidepressants in HIV";
var content_f16_35_16945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antidepressant medications in HIV disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"23%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antidepressant",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical dose range",
"        <br/>",
"        (see NOTE below)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tolerability profile relevant to management of patients with HIV",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of interaction with HIV antiretroviral drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected pharmacokinetic interactions with HIV antiretroviral drugs and management suggestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Selective serotonin reuptake inhibitors (SSRIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citalopram",
"       </td>",
"       <td>",
"        20 mg daily",
"       </td>",
"       <td>",
"        20 to 40 mg daily*",
"       </td>",
"       <td rowspan=\"2\">",
"        Applies to citalopram and escitalopram: Generally well tolerated; effective for anxiety; low risk of sleep disturbance.",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Citalopram and escitalopram are metbolized by CYP2C19 and 3A4",
"        </p>",
"        Neither citalopram nor escitalopram significantly alter CYP metabolism",
"       </td>",
"       <td>",
"        <p>",
"         Applies to citalopram:",
"        </p>",
"        <p>",
"         Possible elevated risk of cardiac arrhythmia in combination with agents that increase citalopram concentrations and/or prolong QTc interval.",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        Citalopram dose should not exceed 20 mg per day in patients receiving moderate or strong CYP2C19 inhibitors which may INCREASE citalopram concentrations, including* efavirenz (variable effects) and etravirine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escitalopram",
"       </td>",
"       <td>",
"        10 mg daily",
"       </td>",
"       <td>",
"        10 to 20 mg daily",
"       </td>",
"       <td>",
"        Applies to escitalopram: Low risk of significant drug interactions with HIV antiretrovirals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sertraline",
"       </td>",
"       <td>",
"        25 to 50 mg daily",
"       </td>",
"       <td>",
"        100 to 200 mg daily",
"       </td>",
"       <td>",
"        <p>",
"         Non-sedating; low risk of insomnia; lacks significant cardiac effects.",
"        </p>",
"        More frequent diarrhea.",
"       </td>",
"       <td>",
"        <p>",
"         Sertraline is metabolized CYP2D6",
"        </p>",
"        Sertraline is an inhibitor of CYP2D6 at doses &ge;200 mg daily",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2D6 including cobicistat containing coformulations, lopinavir-ritonavir, and tipranavir may INCREASE sertraline concentrations.",
"        </p>",
"        <p>",
"         Low dose (ie 100 to 200 mg) ritonavir for pharmacokinetic \"boosting\" of protease inhibitors is less likely to cause a significant interaction.",
"        </p>",
"        <p>",
"         Efavirenz and darunavir-ritonavir DECREASED sertraline AUCs by 39 and 49 percent respectively in small studies of healthy volunteers. Nevirapine may have a similar effect.",
"        </p>",
"        Titrate sertraline dose based on response.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoxetine",
"       </td>",
"       <td>",
"        10 mg daily",
"       </td>",
"       <td>",
"        20 to 40 mg daily",
"       </td>",
"       <td>",
"        <p>",
"         Activating effect may be useful for treatment of depressed patients with low energy or hypersomnia.",
"        </p>",
"        Tapering upon discontinuation is not needed due to long half-life.",
"       </td>",
"       <td>",
"        <p>",
"         Fluoxetine is metabolized by CYP2C19 and 2D6",
"        </p>",
"        Fluoxetine is an inhibitor of CYP1A2, 2C9, 2C19 and 2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2D6, including cobicistat containing coformulations, darunavir, lopinavir-ritonavir, ritonavir, and tipranavir may INCREASE fluoxetine concentrations.",
"        </p>",
"        <p>",
"         Possible elevated risk of cardiac arrhythmia in combination with other agents that prolong QTc interval and/or increase fluoxetine concentrations.",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         Low dose (ie 100 to 200 mg) ritonavir for pharmacokinetic \"boosting\" of protease inhibitors is less likely to cause a significant interaction.",
"        </p>",
"        <p>",
"         Strong inducers of CYP2C19 and/or 2D6, including nevirapine, can DECREASE fluoxetine concentrations.",
"        </p>",
"        Long half-life of fluoxetine may complicate evaluation of response, effect of interactions, and wash-out.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxetine",
"       </td>",
"       <td>",
"        10 mg each bedtime",
"       </td>",
"       <td>",
"        20 to 50 mg each bedtime",
"       </td>",
"       <td>",
"        <p>",
"         Sedating; possibly useful for depressed or anxious patients with insomnia.",
"        </p>",
"        Mild anticholinergic effects.",
"       </td>",
"       <td>",
"        <p>",
"         Paroxetine is metabolized by CYP2D6",
"        </p>",
"        Paroxetine is an inhibitor of CYP2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2D6 including cobicistat containing coformulations, lopinavir-ritonavir and tipranavir may INCREASE paroxetine concentrations.",
"        </p>",
"        <p>",
"         Low dose (ie 100 to 200 mg) ritonavir for pharmacokinetic \"boosting\" of protease inhibitors is less likely to cause a significant interaction.",
"        </p>",
"        <p>",
"         Darunavir-ritonavir and fosamprenavir-ritonavir DECREASED paroxetine AUC by 39 percent and 55 percent respectively in small studies of healthy volunteers.",
"        </p>",
"        Titrate paroxetine dose based upon response.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        50 mg each bedtime",
"       </td>",
"       <td>",
"        150 to 250 mg each bedtime",
"       </td>",
"       <td>",
"        Somewhat sedating.",
"       </td>",
"       <td>",
"        <p>",
"         Fluvoxamine is metabolized by CYPs1A2 and 2D6",
"        </p>",
"        Fluvoxamine is an inhibitor of CYPs1A2 and 2C19",
"       </td>",
"       <td>",
"        Significant drug interactions. Strong inhibitors of CYP1A2 and/or 2D6 including cobicistat containing coformulations, darunavir, lopinavir, lopinavir/ritonavir, and tipranavir may INCREASE fluvoxamine concentrations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Serotonin-norepinephrine reuptake inhibitors (SNRIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duloxetine",
"       </td>",
"       <td>",
"        30 mg",
"       </td>",
"       <td>",
"        60 to 120 mg each bedtime or in divided doses",
"       </td>",
"       <td>",
"        Mildly sedating; useful for patients with comorbid painful conditions such as neuropathy or chronic pain.",
"       </td>",
"       <td>",
"        Duloxetine is metabolized by CYPs1A2 and 2D6",
"       </td>",
"       <td>",
"        Significant drug interactions. Strong inhibitors of CYPs 1A2 and/or 2D6 including cobicistat containing coformulations, darunavir, lopinavir, lopinavir/ritonavir, and tipranavir may INCREASE duloxetine concentrations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desvenlafaxine",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"       <td>",
"        50 to 100 mg once daily",
"       </td>",
"       <td rowspan=\"3\">",
"        Applies to venlafaxine and desvenlafaxine: Activating effect may be useful for treatment of melancholic depressed patients with low energy or hypersomnia. Useful for patients with comorbid painful conditions such as diabetic neuropathy.",
"       </td>",
"       <td>",
"        <p>",
"         Desvenlafaxine undergoes UDP-UGT conjugation and is metabolized by CYP3A4 (minor)",
"        </p>",
"        Duloxetine does not alter CYP metabolism",
"       </td>",
"       <td>",
"        Desvenlafaxine has a low risk of significant interactions with HIV antiretroviral medications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine (extended release)",
"       </td>",
"       <td>",
"        37.5 mg",
"       </td>",
"       <td>",
"        75 to 225 mg once daily",
"       </td>",
"       <td rowspan=\"2\">",
"        Venlafaxine is metabolized by CYPs 2D6 and 3A4",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Strong inhibitors of CYP2D6 and/or 3A4 including atazanavir, cobicistat containing coformulations, darunavir, fosamprenavir, indinavir, lopinavir, lopinavir-ritonavir, nelfinavir, saquinavir, and tipranavir may INCREASE venlafaxine concentrations.",
"        </p>",
"        <p>",
"         Venlafaxine co-administered with saquinavir (with or without ritonavir) may prolong QTc interval.",
"        </p>",
"        <p>",
"         AUC of indinavir (without ritonavir) was decreased by 28 percent by venlafaxine in a small study of healthy volunteers.",
"        </p>",
"        Strong inducers of CYP2D6 and/or 3A4 including efavirenz (variable effects), etravirine, and nevirapine may DECREASE venlafaxine concentrations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine (immediate release)",
"       </td>",
"       <td>",
"        37.5 mg once or twice per day",
"       </td>",
"       <td>",
"        75 to 375 mg per day in two or three divided doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Noradrenergic and specific serotonergic antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mirtazapine",
"       </td>",
"       <td>",
"        7.5 to 15 mg each bedtime",
"       </td>",
"       <td>",
"        15 to 45 mg each bedtime",
"       </td>",
"       <td>",
"        Sedating; useful for patients with insomnia or who may benefit from weight gain which can be substantial. Appetite stimulant and anti-nausea effects can be noted within days.",
"       </td>",
"       <td>",
"        Mirtazapine is metabolized by CYPs 1A2, 2D6 and 3A4",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP1A2, 2D6 and/or 3A4 including atazanavir, cobicistat containing coformulations, darunavir, fosamprenavir, indinavir, lopinavir, lopinavir-ritonavir, nelfinavir, saquinavir, and tipranavir may INCREASE mirtazapine concentrations.",
"        </p>",
"        Strong inducers of CYP 3A4 including efavirenz (variable effects), etravirine (variable effects) and nevirapine may DECREASE mirtazapine concentrations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Serotonin modulators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Trazodone",
"       </td>",
"       <td rowspan=\"2\">",
"        50 to 100 mg each bedtime",
"       </td>",
"       <td>",
"        50 to 150 mg each bedtime for sleep",
"       </td>",
"       <td rowspan=\"2\">",
"        Used in low doses as an adjunct to SSRI for treatment of insomnia.",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Trazodone is metabolized by CYP1A2, 2D6 and 3A4",
"        </p>",
"        Trazodone is a Pgp inducer",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Strong inhibitors of CYP1A2, 2D6 and/or 3A4, including all HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and cobicistat containing coformulations have been shown to INCREASE concentrations of trazodone. Use lowest starting dose of trazodone. Closely monitor effects.",
"        </p>",
"        <p>",
"         <strong>",
"          NOTE:",
"         </strong>",
"         Use of saquinavir or saquinavir-ritonavir with trazodone is contraindicated. Do NOT coadminister.",
"        </p>",
"        <p>",
"         Strong inducers of CYP3A4 including efavirenz (variable effects), etravirine (variable effects) and nevirapine may DECREASE trazodone levels.",
"        </p>",
"        Trazodone may alter concentrations of Pgp substrates including fosamprenavir, indinavir, lopinavir, nelfinavir, and ritonavir.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 to 600 mg each bedtime for depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vilazodone",
"       </td>",
"       <td>",
"        10 mg once daily 7 days; then 20 mg once daily",
"       </td>",
"       <td>",
"        <p>",
"         20 to 40 mg once daily",
"        </p>",
"        Maximum 20 mg per day with strong or moderate CYP 3A4 inhibitors",
"       </td>",
"       <td>",
"        <p>",
"         Low risk of sexual dysfunction. May improve quality of sleep.",
"        </p>",
"        More frequent diarrhea, nausea and insomnia.",
"       </td>",
"       <td>",
"        Vilazodone is metabolized by CYP3A4 (major), 2C19 (minor) and 2D6 (minor)",
"       </td>",
"       <td>",
"        <p>",
"         Strong and moderate inhibitors of CYP 3A4 including atazanavir, cobicistat containing coformulations, darunavir, efavirenz, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir may INCREASE vilazodone concentrations. Maximum dose 20 mg per day with strong or moderate CYP 3A4 inhibitors.",
"        </p>",
"        Strong inducers of CYP 3A4 including efavirenz, etravirine and nevirapine may DECREASE vilazodone concentrations. Effects may be variable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nefazodone",
"       </td>",
"       <td>",
"        50 mg twice per day",
"       </td>",
"       <td>",
"        300 to 400 mg per day in divided doses",
"       </td>",
"       <td>",
"        <p>",
"         Somewhat sedating. Low risk of sexual dysfunction.",
"        </p>",
"        Rare reports of fatal hepatotoxicity led to market withdrawal in many countries.",
"       </td>",
"       <td>",
"        <p>",
"         Nefazodone is metabolized by CYP2D6 and 3A4",
"        </p>",
"        <p>",
"         Nefazodone is a potent inhibitor of CYP3A4",
"        </p>",
"        Nefazodone is an inducer of Pgp",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          NOTE:",
"         </strong>",
"         AVOID nefazodone in patients treated with HIV antiretrovirals, whenever possible.",
"        </p>",
"        <p>",
"         Not a first- or second-line choice. Numerous dose dependent drug interactions can increase risk of toxicities due to both nefazodone and HIV antiretrovirals.",
"        </p>",
"        <p>",
"         Nefazodone may alter concentrations of CYP 3A4 and/or Pgp substrates including atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, maraviroc, nelfinavir, nevirapine, ritonavir, and saquinavir.",
"        </p>",
"        All HIV protease inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"        and cobicistat containing coformulations, may INCREASE concentrations of nefazodone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Dopamine-norepinephrine reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion SR (sustained release)",
"       </td>",
"       <td>",
"        100 mg each morning",
"       </td>",
"       <td>",
"        150 to 400 mg per day in divided doses (depending on preparation)",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Stimulant effect may be useful for treatment of depressed patients with low energy and apathy.",
"        </p>",
"        Low risk of cognitive toxicity. Low risk of sexual dysfunction.",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Bupropion is metabolized by CYP2B6 and/or UDP-UGT glucuronidation",
"        </p>",
"        Bupropion is an inhibitor of CYP2D6",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Nelfinavir is an inhibitor of CYP2B6 and may INCREASE bupropion concentrations.",
"        </p>",
"        <p>",
"         Strong inducers of CYP2B6 and/or UDP-UGT including efavirenz, lopinavir, lopinavir-ritonavir, tipranavir-ritonavir, and nevirapine may DECREASE concentrations of bupropion.",
"        </p>",
"        <p>",
"         A 46 to 57 percent reduction in bupropion concentrations was reported in small studies of healthy volunteers when bupropion was co-administered with tipranavir-ritonavir, or efavirenz.",
"        </p>",
"        Titrate bupropion dose based upon response.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bupropion XL (extended release)",
"       </td>",
"       <td>",
"        150 mg each morning",
"       </td>",
"       <td>",
"        300 to 450 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Tricyclic antidepressants (TCAs)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desipramine",
"       </td>",
"       <td>",
"        10 to 25 mg daily",
"       </td>",
"       <td>",
"        50 to 300 mg daily",
"       </td>",
"       <td>",
"        Mildly activating; promotes weight gain. Stimulant effects may be useful for depressed patients with low energy and hypersomnia who have not responded to first line antidepressants. Useful for patients with comorbid painful conditions such as diabetic neuropathy. Established therapeutic serum concentration 125 to 300 ng/mL.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Desipramine is metabolized by CYP2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2D6, all HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         may INCREASE desipramine concentrations.",
"        </p>",
"        <p>",
"         Use lowest tricyclic antidepressant dose and titrate based on response and/or antidepressant concentrations.",
"        </p>",
"        Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation or increase desipramine concentrations.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortriptyline",
"       </td>",
"       <td>",
"        10 to 25 mg at bed time",
"       </td>",
"       <td>",
"        50 to 150 mg at bedtime",
"       </td>",
"       <td>",
"        Mildly sedating; promotes weight gain. Taken at bed time for depressed patients with insomnia. May be useful for melancholic, anxious, depressed patients who have not responded to first line antidepressants. Useful for patients with comorbid painful conditions such as diabetic neuropathy. Established therapeutic serum concentration 50 to 150 ng/mL.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Nortriptyline is metabolized by CYP2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2D6 including all HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and cobicistat containing coformulations, may INCREASE nortriptyline concentrations.",
"        </p>",
"        <p>",
"         Use lowest tricyclic antidepressant dose and titrate based on response and/or antidepressant concentrations.",
"        </p>",
"        Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation or increase nortriptyline concentrations.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amitriptyline",
"       </td>",
"       <td>",
"        10 to 25 mg daily",
"       </td>",
"       <td>",
"        150 to 300 mg daily",
"       </td>",
"       <td>",
"        Sedating; promotes weight gain.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Amitriptyline is metabolized by CYP2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2D6 including all HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and cobicistat containing coformulations, may INCREASE amitriptyline concentrations.",
"        </p>",
"        <p>",
"         Use lowest tricyclic antidepressant dose and titrate based on response.",
"        </p>",
"        Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation or increase amitriptyline concentrations.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clomipramine",
"       </td>",
"       <td>",
"        25 mg at bedtime",
"       </td>",
"       <td>",
"        100 to 300 mg at bedtime",
"       </td>",
"       <td>",
"        Sedating; promotes weight gain.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Clomipramine is metabolized by CYP1A2, 2C19 and 2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP1A2, 2C19 and/or 2D6, including all HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and cobicistat containing coformulations, may INCREASE clomipramine concentrations.",
"        </p>",
"        <p>",
"         Use lowest tricyclic antidepressant dose and titrate based on response.",
"        </p>",
"        Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation or increase clomipramine concentrations.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imipramine",
"       </td>",
"       <td>",
"        10 to 25 mg at bedtime",
"       </td>",
"       <td>",
"        150 to 300 mg at bedtime",
"       </td>",
"       <td>",
"        Sedating; promotes weight gain.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Imipramine is metabolized by CYP2C19 and 2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2C19 and/or 2D6 including all HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and cobicistat containing coformulations, may INCREASE imipramine levels.",
"        </p>",
"        <p>",
"         Use lowest tricyclic antidepressant dose and titrate based on response.",
"        </p>",
"        Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation or increase imipramine concentrations.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxepin",
"       </td>",
"       <td>",
"        10 to 25 mg at bedtime",
"       </td>",
"       <td>",
"        150 to 300 mg at bed time",
"       </td>",
"       <td>",
"        Sedating; promotes weight gain.",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Doxepin is metabolized by CYP2D6",
"       </td>",
"       <td>",
"        <p>",
"         Strong inhibitors of CYP2D6 including all HIV protease inhibitors",
"         <sup>",
"          &Delta;",
"         </sup>",
"         and cobicistat containing coformulations, may INCREASE doxepin concentrations.",
"        </p>",
"        <p>",
"         Use lowest tricyclic antidepressant dose and titrate based on response.",
"        </p>",
"        Elevated risk of serious cardiac arrhythmias in combination with other agents that can cause QTc prolongation or increase doxepin concentrations.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Herbal products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        St John's wort (Hypericum perforatum)",
"       </td>",
"       <td colspan=\"3\">",
"        <strong>",
"         Do NOT co-administer St John's wort with HIV antiretroviral drugs.",
"        </strong>",
"       </td>",
"       <td>",
"        St John's wort is an inducer of CYP1A2, 2C9, and 3A4",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Concomitant use of St John's wort and HIV antiretroviral drugs is contraindicated.",
"         </strong>",
"        </p>",
"        Use of St John's wort with all HIV protease inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , efavirenz, etravirine, nevirapine, and maraviroc can DECREASE antiretroviral concentrations and cause virologic resistance and treatment failure.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     IMPORTANT NOTE: Not all potential interactions are listed.",
"    </strong>",
"    Additional interactions of antidepressants with other medications taken by HIV patients and management suggestions may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. Agents are listed within each class in order of preference based upon tolerability in most patients.",
"    <br/>",
"    <strong>",
"     Use doses at the lower end of ranges shown for starting and maintenance treatment of depression in patients with HIV who are medically ill, older or debilitated.",
"    </strong>",
"    <div class=\"footnotes\">",
"     AUC: area under the time versus concentration curve; CYP: cytochrome P450; Pgp: P-glycoprotein efflux transporter; UDP-UGT: uridine 5'-diphospho-glucuronosyltransferase catalyst of glucuronidation.",
"     <br/>",
"     * Maximum recommended dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking medications that can increase citalopram levels. For additional information, refer to UpToDate topic on selective serotonin reuptake inhibitors (SSRIs) section on cardiac side effects.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     QTc prolonging antidepressant drugs can have additive effects with other drugs that prolong the QTc interval, including saquinavir, and may cause life-threatening ventricular arrhythmias. Refer to topics on selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants for treating depressed adults.",
"     <br/>",
"     &Delta; HIV protease inhibitors include: atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Due to significant anticholinergic side effects, tricyclic antidepressants (TCAs) may NOT be well tolerated in patients with HIV who are also medically ill. TCAs may be fatal in overdose and can cause cardiac arrhythmias or orthostatic hypotension. Serum drug concentration monitoring may be useful for guiding treatment with amitriptyline, desipramine, imipramine, and nortriptyline. For additional information refer to UpToDate topic on unipolar depression and tricyclic and tetracyclic drugs for treating depressed adults.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Lacy CF, et al (eds) Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"      </li>",
"      <li>",
"       Wynn GH, et al (eds) Clinical Manual of Drug Interaction Principles for Medical Practice APA publishing, Washington DC. Copyright &copy; 2009.",
"      </li>",
"      <li>",
"       Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1&ndash;239. Available at",
"       <a href=\"file://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">",
"        file://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf",
"       </a>",
"       . Drug interactions section accessed April 18, 2012.",
"      </li>",
"      <li>",
"       Hill L and Lee KC Pharmacotherapy considerations in patients with HIV and psychiatric disorders: Focus on antidepressants and antipsychotics. Ann Pharmacother 2013;47:75.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16945=[""].join("\n");
var outline_f16_35_16945=null;
var title_f16_35_16946="Patient information: Aseptic meningitis (The Basics)";
var content_f16_35_16946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/1/31762\">",
"         Patient information: Bacterial meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/43/3763\">",
"         Patient information: Meningitis in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/34/28194\">",
"         Patient information: Viral meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/48/1796\">",
"         Patient information: Meningitis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Aseptic meningitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/aseptic-meningitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H4565541\">",
"      <span class=\"h1\">",
"       What is meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Meningitis is a condition that can cause a fever, headache, and stiff neck. Meningitis happens when the lining that covers the brain and spinal cord (called the &ldquo;meninges&rdquo;) gets inflamed or infected.",
"     </p>",
"     <p>",
"      An infection of the meninges can happen after a person gets an infection in another part of the body. The germs can travel through the blood to the lining of the brain and spinal cord.",
"     </p>",
"     <p>",
"      There are 2 main types of meningitis:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bacterial meningitis",
"       </li>",
"       <li>",
"        Aseptic meningitis",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Bacterial meningitis is caused by bacteria. Aseptic meningitis is not. It&rsquo;s important for doctors to find out which kind of meningitis a person has, because bacterial meningitis is a medical emergency. It can lead to brain problems or even death.",
"     </p>",
"     <p>",
"      Aseptic meningitis is serious, but not usually as serious as bacterial meningitis. People usually recover from aseptic meningitis without any long-term problems.",
"     </p>",
"     <p>",
"      Both aseptic and bacterial meningitis can have the same symptoms. So the only way a doctor can know for sure which type of meningitis someone has is to do tests in the hospital.",
"     </p>",
"     <p>",
"      This article discusses aseptic meningitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4565556\">",
"      <span class=\"h1\">",
"       What causes aseptic meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Viruses cause most cases of aseptic meningitis. But other things can also cause aseptic meningitis, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Germs that are not bacteria or viruses",
"       </li>",
"       <li>",
"        Medicines &ndash; Aseptic meningitis can be a rare side effect of certain medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Also, people who have advanced cancer can get aseptic meningitis if their cancer spreads to their meninges.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4565571\">",
"      <span class=\"h1\">",
"       What are the symptoms of aseptic meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Stiff neck &ndash; This is most often seen in children and adults. Babies might not get a stiff neck.",
"       </li>",
"       <li>",
"        Having light bother a person&rsquo;s eyes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Babies can also have other symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not feeding well",
"       </li>",
"       <li>",
"        Being more sleepy or fussy than usual",
"       </li>",
"       <li>",
"        A bulging soft spot on the skull",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People can have other symptoms, too, depending on what&rsquo;s causing the infection. For example, people whose aseptic meningitis is caused by a virus can also have a rash, diarrhea, runny nose, or sore throat. A rash can also happen with bacterial meningitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4565586\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have a fever, headache, and stiff neck, go to the emergency room right away. If you think your child has meningitis, bring him or her to the emergency room right away.",
"     </p>",
"     <p>",
"      It&rsquo;s very important to go to the hospital if you think you or your child has meningitis. That&rsquo;s because the only way a doctor can tell for sure that someone has aseptic meningitis &ndash; and not life-threatening bacterial meningitis &ndash; is to do tests in the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4565601\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will learn about your symptoms and do an exam. He or she will do tests to look for the cause of your meningitis. These tests can include 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a thin needle into your lower back and takes out a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid.",
"       </li>",
"       <li>",
"        A CT scan of the brain &ndash; This is an imaging test that creates pictures of the brain.",
"       </li>",
"       <li>",
"        Other tests &ndash; For example, the doctor can use a cotton swab to collect a sample from the back of the throat. Then he or she can do lab tests on the sample.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4565618\">",
"      <span class=\"h1\">",
"       How is aseptic meningitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for aseptic meningitis usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Resting",
"       </li>",
"       <li>",
"        Drinking fluids or getting fluids into your vein through a tube called an &ldquo;IV&rdquo;",
"       </li>",
"       <li>",
"        Taking an over-the-counter medicine to treat a fever or headache",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Aseptic meningitis is NOT treated with antibiotic medicines. That&rsquo;s because antibiotics only treat infections caused by bacteria.",
"     </p>",
"     <p>",
"      Your doctor might recommend other treatments, depending on what&rsquo;s causing the meningitis. Certain viruses and other germs can be treated with medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4565633\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/34/28194?source=see_link\">",
"       Patient information: Viral meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       Patient information: Bacterial meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=see_link\">",
"       Patient information: Meningitis in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=see_link\">",
"       Patient information: Meningitis in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/35/16946?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16954 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16946=[""].join("\n");
var outline_f16_35_16946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4565541\">",
"      What is meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4565556\">",
"      What causes aseptic meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4565571\">",
"      What are the symptoms of aseptic meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4565586\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4565601\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4565618\">",
"      How is aseptic meningitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4565633\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/43/3763?source=related_link\">",
"      Patient information: Meningitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/34/28194?source=related_link\">",
"      Patient information: Viral meningitis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_35_16947="Acyclovir and hydrocortisone: Drug information";
var content_f16_35_16947=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acyclovir and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/1/2068?source=see_link\">",
"    see \"Acyclovir and hydrocortisone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/56/39811?source=see_link\">",
"    see \"Acyclovir and hydrocortisone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12586583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xerese&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12586587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent, Topical;",
"     </li>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12586630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Herpes labialis (cold sores):",
"     </b>",
"     Topical: Apply 5 times/day for 5 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12586629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/56/39811?source=see_link\">",
"      see \"Acyclovir and hydrocortisone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Herpes labialis (cold sores):",
"     </b>",
"     Topical: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12586631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14876700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xerese&reg;: Acyclovir 5% and hydrocortisone 1% (5 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12586585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12586632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; not for use in the eye, inside the mouth or nose, or on the genitals. Apply to clean, dry area using a finger cot or rubber glove to avoid transmission to other parts of the body or to other persons. Use sufficient amount to cover the affected area(s), including the outer margin of cold sore; do not rub affected area. Initiate therapy early (ie, during the prodrome or when lesions appear).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12586589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of recurrent herpes labialis (cold sores)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12586598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Dermatologic: Burning, contact dermatitis, dryness, erythema, flaking, pigmentation changes, sensitization, signs/symptoms of inflammation, tingling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12586594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12586595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sensitization: Use has been associated with local sensitization (irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Herpes labialis: Appropriate use: Treatment should begin with the first signs or symptoms. For external use only to the lips and around the mouth; do not apply to eye, inside the mouth or nose, or on the genitals. Contact healthcare provider if cold sore does not heal in 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunocompromised patients: Use with caution in immunocompromised patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12586601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12586590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12586591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies and studies in pregnant women have not been conducted with Xerese&trade;.  Systemic exposure of acyclovir and hydrocortisone after topical administration is minimal. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12586592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12586593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic exposure of acyclovir and hydrocortisone after topical administration is minimal. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Xerese External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1% (5 g): $389.95",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Xerclear (CZ, DK, FI, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12586607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12586609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hull CM, Harmenberg J, Arlander E, et al, &ldquo;Early Treatment of Cold Sores With Topical ME-609 Decreases the Frequency of Ulcerative Lesions: A Randomized, Double-Blind, Placebo-Controlled, Patient-Initiated Clinical Trial,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2011, 64(4):696.e1-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/35/16947/abstract-text/20851499/pubmed\" id=\"20851499\" target=\"_blank\">",
"        20851499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16477 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-063D528ED5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16947=[""].join("\n");
var outline_f16_35_16947=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586583\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586587\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586630\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586629\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586631\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14876700\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586585\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586632\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586589\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586598\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586594\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586595\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298684\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586601\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586590\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586591\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586592\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586593\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570430\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733204\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586607\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586609\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/1/2068?source=related_link\">",
"      Acyclovir and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/56/39811?source=related_link\">",
"      Acyclovir and hydrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_35_16948="Iodixanol: Patient drug information";
var content_f16_35_16948=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Iodixanol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/63/13301?source=see_link\">",
"     see \"Iodixanol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23124?source=see_link\">",
"     see \"Iodixanol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Visipaque&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9746694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Visipaque&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is given as a shot into a vein or artery only.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to iodixanol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12213 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16948=[""].join("\n");
var outline_f16_35_16948=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183727\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9746694\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025936\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025938\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025937\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025941\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025942\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025944\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025940\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025945\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025946\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/63/13301?source=related_link\">",
"      Iodixanol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/37/23124?source=related_link\">",
"      Iodixanol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_35_16949="Haemophilus influenzae type b conjugate and hepatitis B vaccine: Drug information";
var content_f16_35_16949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Haemophilus influenzae type b conjugate and hepatitis B vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/26/13729?source=see_link\">",
"    see \"Haemophilus influenzae type b conjugate and hepatitis B vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24340?source=see_link\">",
"    see \"Haemophilus influenzae type b conjugate and hepatitis B vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Comvax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F178308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial);",
"     </li>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F178304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24340?source=see_link\">",
"      see \"Haemophilus influenzae type b conjugate and hepatitis B vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     Infants: I.M.: 0.5 mL/dose; one dose at 2, 4, and 12-15 months of age (total of 3 doses).",
"     <b>",
"      Note:",
"     </b>",
"     If the recommended schedule cannot be followed, the interval between the first two doses should be at least 6 weeks and the interval between the second and third dose should be as close as possible to 8-11 months. Minimum age for first dose is 6 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Modified Schedule:",
"     </b>",
"     Children who receive one dose of hepatitis B vaccine at or shortly after birth may receive Comvax&reg; on a schedule of 2, 4, and 12-15 months of age",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Comvax&reg;:",
"     <i>",
"      Haemophilus",
"     </i>",
"     b capsular polysaccharide 7.5 mcg (bound to",
"     <i>",
"      Neisseria meningitides",
"     </i>",
"     OMPC 125 mcg) and hepatitis B surface antigen 5 mcg per 0.5 mL (0.5 mL) [contains aluminum; contains natural rubber/natural latex in packaging]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F178289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well prior to use. Administer 0.5 mL I.M. into anterolateral thigh [data suggests that injections given in the buttocks frequently are given into fatty tissue instead of into muscle and result in lower seroconversion rates];",
"     <b>",
"      do not administer intravenously, intradermally, or subcutaneously.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered with by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F178288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immunization against invasive disease caused by",
"     <i>",
"      H. influenzae",
"     </i>",
"     type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born of hepatitis B surface antigen (HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag)-negative mothers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants born of HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive mothers or mothers of unknown HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag status should receive hepatitis B vaccine (recombinant) at birth and should complete the hepatitis B vaccination series given according to a particular schedule (refer to current ACIP recommendations).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F178315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Comvax&reg; may be confused with Recombivax [Recombivax HB&reg;]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F178306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Irritability (32% to 57%), somnolence (21% to 50%), fever (101&deg;F to 102.9&deg;F: 11% to 14%), crying (unusual/high pitched: 3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Pain/soreness (24% to 35%), swelling/induration (&ge;1 inch: 27% to 30%), erythema (&ge;1 inch: 22% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (&ge;103&deg;F: &lt;1% to 3%), crying (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (&lt;1% to 4%), vomiting (1% to 3%), diarrhea (&lt;1% to 2%), oral candidiasis (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Erythema (&gt;1 inch: 1% to 3%), swelling/induration (&gt;1 inch: 3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (&lt;1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: cough (&le;1%), respiratory congestion (&le;1%), rhinorrhea (&le;1%), upper respiratory tract infection (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis, angioedema, erythema multiforme, febrile seizure, seizure, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F178292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to",
"     <i>",
"      Haemophilus",
"     </i>",
"     b vaccine, hepatitis B vaccine, yeast, or to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F178277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute febrile illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy (including high dose corticosteroids)); may have a reduced response to vaccination. May be used in patients with HIV infection. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging contains natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Comvax&reg; is not indicated for use as the &ldquo;birth dose&rdquo; of hepatitis B vaccine; hepatitis B vaccine (recombinant) is indicated for all infants at birth. This combination vaccine cannot be administered to any infant &lt;6 weeks of age or &gt;71 months of age. Infants born of HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive mothers or mothers of unknown HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag status should receive hepatitis B vaccine (recombinant) at birth and should complete the hepatitis B vaccination series given according to a particular schedule (refer to current ACIP recommendations). Infants born of HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive mothers should also receive hepatitis B immune globulin at birth.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011). Infection may occur within the week of vaccination, prior to the onset of the vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F178295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. This product is not indicated for use in women of childbearing age.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Comvax Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5-5 mcg/0.5 mL (0.5 mL): $51.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13908723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Comvax (MX);",
"     </li>",
"     <li>",
"      Procomvax (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HN, IE, IT, NL, NO, PT, RU, SE, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F178276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F178291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part I: Immunization of Infants, Children, and Adolescents,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-16):1-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/35/16949/abstract-text/16371945/pubmed\" id=\"16371945\" target=\"_blank\">",
"        16371945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/35/16949/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/35/16949/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/35/16949/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8635 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16949=[""].join("\n");
var outline_f16_35_16949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178299\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178308\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178304\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897413\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897414\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178286\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178273\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178289\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178288\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178315\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178306\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178292\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178277\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299432\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178280\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178282\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178295\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323179\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13908723\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539873\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178276\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178291\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8635\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8635|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/26/13729?source=related_link\">",
"      Haemophilus influenzae type b conjugate and hepatitis B vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24340?source=related_link\">",
"      Haemophilus influenzae type b conjugate and hepatitis B vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_35_16950="Reserpine: Drug information";
var content_f16_35_16950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Reserpine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/7/6261?source=see_link\">",
"    see \"Reserpine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Monoamine-Depleting Agent;",
"     </li>",
"     <li>",
"      Rauwolfia Alkaloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F249804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-4em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Manufacturer's labeling:",
"     </i>",
"     Initial: 0.5 mg/day for 1-2 weeks; maintenance: 0.1-0.25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Clinically, the need for a &ldquo;loading&rdquo; period (as recommended by the manufacturer) is not well supported, and alternative dosing is preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Alternative dosing (unlabeled):",
"     </i>",
"     Initial: 0.1 mg once daily; adjust as necessary based on response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Usual dose range (JNC 7):",
"     </i>",
"     0.05-0.25 mg once daily; 0.1 mg every other day may be given to achieve 0.05 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Schizophrenia (labeled use) or tardive dyskinesia (unlabeled use):",
"     </b>",
"     Dosing recommendations vary; initial dose recommendations generally range from 0.05-0.25 mg (although manufacturer recommends 0.5 mg once daily initially in schizophrenia). May be increased in increments of 0.1-0.25 mg; maximum dose in tardive dyskinesia: 5 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F217707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children: Hypertension: 0.01-0.02 mg/kg/24 hours divided every 12 hours; maximum dose: 0.25 mg/day (not recommended in children)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 0.05 mg once daily increasing by 0.05 mg every week as necessary; full antihypertensive effects may take as long as 3 weeks (Beers Criteria: Avoid doses &gt;0.25 mg daily)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F217697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.1 mg, 0.25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of mild-to-moderate hypertension; treatment of agitated psychotic states (schizophrenia)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F217714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of tardive dyskinesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Reserpine may be confused with RisperDAL&reg;, risperiDONE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, chest pain, hypotension, peripheral edema, PVC, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness,  dull sensorium, fatigue, headache, mental depression, nightmares, nervousness, parkinsonism, paradoxical anxiety",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Flushing of skin, pruritus, purpura, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dry mouth, gastric acid secretion increased, nausea, salivation increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle ache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, optic atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, nasal congstion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to reserpine or any component of the formulation; active peptic ulcer disease, ulcerative colitis; history of mental depression (especially with suicidal tendencies); patients receiving electroconvulsive therapy (ECT)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: At high doses, significant mental depression, anxiety, or psychosis may occur (uncommon at dosages &lt;0.25 mg/day).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of hypotension or in patients where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallstones: Use with caution in patients with gallstones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with inflammatory bowel disease or history of peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson&rsquo;s disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors:   Avoid concurrent use of MAO inhibitors and/or drugs with MAO-inhibiting properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid using doses &gt;0.1 mg/day of reserpine due to high risk of CNS adverse effects; may also cause orthostatic hypotension and bradycardia; not recommended for routine use as an antihypertensive (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroshock therapy: Discontinue reserpine 7 days before electroshock therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Gastrointestinal Acidifying Agents may decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Reserpine may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Reserpine may enhance the adverse/toxic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Reserpine may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension). Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Reserpine may enhance the adverse/toxic effect of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: Reserpine may enhance the adverse/toxic effect of Tetrabenazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F217689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe (may worsen hypertension). Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reserpine crosses the placenta. Teratogenic events have been observed in animal reproduction studies with parenteral administration. Nonteratogenic effects in the newborn following reserpine exposure include anorexia, cyanosis, nasal congestion, and increased respiratory tract secretions.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13817243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reserpine is excreted into human breast milk; anorexia, cyanosis, nasal congestion, and increased respiratory tract secretions have been reported in nursing infants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F217679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Reserpine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg (100): $119.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mg (100): $164.71",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, standing and sitting/supine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Raupasil (BG, PL);",
"     </li>",
"     <li>",
"      Rauserpine (TW);",
"     </li>",
"     <li>",
"      Rauverid (PH);",
"     </li>",
"     <li>",
"      Respine (MY);",
"     </li>",
"     <li>",
"      Serpasil (ID, IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces blood pressure via depletion of sympathetic biogenic amines (norepinephrine and dopamine); this also commonly results in sedative effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antihypertensive: 3-6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic (&gt;90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 50-100 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (30% to 60%); urine (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/35/16950/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/35/16950/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9855 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16950=[""].join("\n");
var outline_f16_35_16950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217717\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F249804\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217707\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217696\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217697\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217670\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217654\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217673\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217714\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217722\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217715\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217676\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217658\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838494\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217663\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217689\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217665\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206277\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217699\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13817243\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217679\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217668\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217680\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217657\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217675\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9855\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9855|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/7/6261?source=related_link\">",
"      Reserpine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_35_16951="EUS FNA sarcoidosis";
var content_f16_35_16951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of a mediastinal lymph node from a patient with sarcoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16951=[""].join("\n");
var outline_f16_35_16951=null;
var title_f16_35_16952="Full body CT scan for screening";
var content_f16_35_16952=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Full body CT scan for screening",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Jeffrey L Jackson, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Elizabeth Berbano, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Patrick O'Malley, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16952/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/35/16952/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full-body computed tomography (FBCT) scans and other advanced-technology screening tests are increasingly being marketed directly to consumers to detect subclinical disease. A number of factors have fostered the popularity of total body imaging among the nonmedical community, including advances in diagnostic imaging, public interest in health promotion and disease prevention, positive celebrity endorsements, and media attention.",
"   </p>",
"   <p>",
"    Though not generally covered by health insurance, these screening procedures are being marketed to relatively healthy, asymptomatic individuals who have the financial resources to afford the direct costs of the test. A multicenter study in the United States (US) found that nearly all patients believed that FBCT would provide personal reassurance about their health and that it could diagnose cancers while still curable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority believed that FBCT was one of the best preventive medicine options available. A US national telephone survey of 500 adults on public enthusiasm for cancer screening, including total body imaging, revealed that 86 percent wished to have a free FBCT, if offered; 85 percent preferred FBCT to receiving $1000 in cash [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, the number of self-referred body imaging centers doubled between 2001 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/3\">",
"     3",
"    </a>",
"    ]. Recognition of this demand for screening is important to clinicians as they counsel patients on the risks and benefits of these diagnostic techniques, both at the clinical level as well as in the broader social context of health care economics, quality, and policy.",
"   </p>",
"   <p>",
"    There are limited data on the risks and benefits of total body imaging and no published randomized, controlled trials. Since CT is currently the most widely used imaging modality deployed for full-body screening, this topic reviews the rationale and utility of screening with FBCT. Screening with magnetic resonance imaging (MRI), positron emission tomography, or other advanced imaging techniques are not specifically discussed, although the principles apply to these technologies as well. Total body imaging may have appropriate uses in nonscreening settings such as for the detection of metastatic disease or assessing tumor burden [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], but this review only deals with the use of total body imaging for screening purposes.",
"   </p>",
"   <p>",
"    General issues of radiation-related risk of imaging studies and clinical features of radiation injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a national US survey, 87 percent of respondents felt that \"routine cancer screening tests for healthy persons are almost always a good idea\" [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/2\">",
"     2",
"    </a>",
"    ]. Although it is common to believe that early detection will lead to better outcomes, this is frequently not the case, and there are important criteria that should be met before any screening program is recommended (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The disease being screened must be reasonably common and have a significant impact on either the duration or quality of life.",
"     </li>",
"     <li>",
"      An acceptable, effective treatment for the disease must exist, and the condition must have an asymptomatic period during which detection and treatment can improve patient outcomes.",
"     </li>",
"     <li>",
"      Treatment during the asymptomatic period must be superior to treatment once symptoms occur.",
"     </li>",
"     <li>",
"      The screening test must be safe, affordable, and have adequate sensitivity and specificity.",
"     </li>",
"     <li>",
"      The screening modality must be acceptable to the patient and to society.",
"     </li>",
"     <li>",
"      There must be evidence of continued effectiveness over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCREENING WITH FBCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order for FBCT to be an appropriate screening test, it must fulfill the above criteria. However, unlike most screening tests, the proponents of FBCT are typically recommending it to screen for multiple diseases simultaneously (generally for coronary heart disease along with multiple types of cancer).",
"   </p>",
"   <p>",
"    There are no data from randomized trials looking at this use of FBCT, but it is possible to extrapolate from information about disease frequency and the performance of CT in screening for the relatively common conditions of lung cancer and coronary heart disease (CHD). Additionally, there are data on the rates of incidental findings during virtual colonoscopy; proponents of virtual colonoscopy cite the potential added benefit of screening for extracolonic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36632?source=see_link\">",
"     \"Computed tomographic colonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;While awaiting results from ongoing randomized controlled trials, current evidence is felt to be inadequate to justify routine screening for lung cancer with chest CT, even in higher risk populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link&amp;anchor=H15#H15\">",
"     \"Screening for lung cancer\", section on 'Screening with chest CT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening asymptomatic individuals for coronary artery calcification using fast CT scanners (including electron beam CT, helical CT, multi-detector CT) is now widely practiced, despite two consecutive position papers from the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association that have recommended against this practice. Although coronary artery calcification may correlate with increased CHD risk, it is not possible to make a clear recommendation for screening without additional data demonstrating benefit of screening coronary CT. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Colon cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of virtual colonoscopy is controversial. One argument that has been made for virtual colonoscopy is that extracolonic abnormalities may be detected as well. Observational studies have shown that extracolonic findings are detected in the majority of patients and that 9 to 12 percent of these require further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. There are no data on whether asymptomatic patients benefit from interventions on such incidentally found abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36632?source=see_link\">",
"     \"Computed tomographic colonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extrapolation to other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening issues discussed for the relatively prevalent conditions of lung cancer and cardiovascular disease have applicability to screening with FBCT for rarer conditions such as other malignancies.",
"   </p>",
"   <p>",
"    If FBCT is favorably assumed to have a sensitivity and specificity of 95 percent for other conditions, then, for example, an individual who has a FBCT reported as detecting hepatocellular carcinoma (baseline yearly incidence in the United States of 2.8 per 100,000 people) can be estimated to have a 5 in 10,000 chance of having hepatocellular carcinoma; there would be more than 1800 false-positive reports of hepatocellular carcinoma for every true-positive report. Additionally, there are no data that early detection of hepatocellular carcinoma with FBCT improves survival.",
"   </p>",
"   <p>",
"    Similar arguments can be made regarding screening with FBCT for other malignancies such as ovarian cancer, lymphoma, and adrenocortical carcinoma.",
"   </p>",
"   <p>",
"    It is possible that screening for abdominal aortic aneurysm (AAA) with ultrasound may be cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/9\">",
"     9",
"    </a>",
"    ]. Abdominal CT is typically somewhat more expensive than ultrasound, but it is likely to be at least as accurate in detecting AAA. Currently, screening for AAA is felt not to have adequate evidence even in a normal-risk elderly population, and so it is unlikely to be cost-effective in a low-risk younger population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for abdominal aortic aneurysm\", section on 'Cost-effectiveness'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=see_link&amp;anchor=H18#H18\">",
"     \"Screening for abdominal aortic aneurysm\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If FBCT is performed and incidental AAA is detected, follow-up evaluations for progression could be performed with ultrasound, improving the overall cost-effectiveness of such screening [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Costs of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to being safe, screening tests must be reasonably inexpensive. Currently total body imaging in the United States costs between $500 and $1000; insurance companies do not routinely cover these tests.",
"   </p>",
"   <p>",
"    In calculating the costs of screening, downstream direct and indirect costs must also be considered. There are costs associated with the evaluation of suspicious findings on FBCT, and many of those evaluations will require missed time from work, leading to additional costs.",
"   </p>",
"   <p>",
"    A cost-effectiveness analysis that included downstream direct costs, but not indirect costs, concluded that one-time screening of 50-year-old men with FBCT would increase life expectancy by an average of six days with a cost of $151,000 per life-year gained (in 2001 US dollars) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/11\">",
"     11",
"    </a>",
"    ]; a threshold of $50,000 per life-year gained is typically considered cost effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although 91 percent of patients had at least one positive finding, only 2 percent had disease. Further evaluation of false positive findings was responsible for 32 percent of total costs. This model was sensitive to assumptions about prevalence of disease, effect of screening on disease stage at diagnosis, specificity, and costs of follow-up; however, even with assumptions favorable to FBCT, one-time screening did not appear to be cost-effective.",
"   </p>",
"   <p>",
"    Cost-effectiveness analyses have also been performed in presumed higher-risk patients where the prevalence of disease is increased. In an analysis that modeled 20 years of annual helical CT, and which assumed a 50 percent stage shift in lung cancer (ie, screened patients would have more localized disease and fewer advanced cancers), the incremental cost effectiveness of screening 60-year-old current, quitting, and former smokers was $116,300, $558,600, and $2,322,700 per quality adjusted life-year (QALY) gained, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/12\">",
"     12",
"    </a>",
"    ]. In a sensitivity analysis, when all influential parameters were simultaneously made highly favorable to CT, a program of screening current smokers had an incremental cost-effectiveness of $42,000 per QALY gained; no adjustment of any single parameter led to the model finding screening to be cost effective.",
"   </p>",
"   <p>",
"    A study that looked at the cost-effectiveness of coronary CT and made assumptions favorable to screening still found that CT was expensive with a cost of approximately $90,000 per QALY saved [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/13\">",
"     13",
"    </a>",
"    ]. When incorporating utilities of being diagnosed as \"at risk\" (ie, a 10-year risk of &gt;10 percent) equivalent to that used for having a diagnosis of high blood pressure (Beaver Dam Health Outcomes = 0.94), screening with coronary CT was dominated by conventional risk prediction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .) According to this analysis, it is unlikely that screening in young asymptomatic populations would be cost-effective unless the independent prognostic value is substantial, primary prevention leads to at least a 25 percent improvement in survival, and the disutility of screening is only marginal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RISKS OF SCREENING WITH FBCT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adverse effects associated with false positives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever a screening test of uncertain benefit is performed in an individual with low risk of disease, even small risks may outweigh the benefits to the few in whom true disease is detected. The most likely outcomes of CT screening of a healthy asymptomatic person are either normal findings or suspicious findings requiring follow-up tests.",
"   </p>",
"   <p>",
"    As discussed above, false-positive results with FBCT are far more common than true-positive results. Thus, any risk to patients from an evaluation necessary to confirm a diagnostic possibility raised by FBCT is multiplied over the large number of patients who will have false-positive results. As an example, some portion of patients without lung cancer who are found on FBCT to have a lesion that is reported as suspicious will be harmed during further diagnostic workup (such as needle biopsy) or by definitive management (such as unnecessary lobectomy). Data suggest that about half of pulmonary nodules that come to surgery and are removed are benign [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. There may be significant morbidity and mortality associated with such surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study where the entire lung fields of smokers were screened with CT, 23 percent of patients were found to have noncalcified lung nodules requiring further evaluation, with a subsequent malignancy found in 1.3 percent of the patients screened [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/18\">",
"     18",
"    </a>",
"    ]; while in another cohort nearly 70 percent of patients were found to have a noncalcified lung nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Lung cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the latter study, there were also 696 additional findings in 1520 patients that were felt to require further testing or intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/15\">",
"     15",
"    </a>",
"    ]. These included 114 AAAs, four renal cell carcinomas, three breast cancers, two lymphomas, two gastric tumors, and one pheochromocytoma. However, most of the additional findings were false positives [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of incidental noncardiac findings on CT screening for coronary artery disease, where approximately 30 percent of the lung fields are imaged along with the heart, 103 of 1326 patients (7.8 percent) had significant extracardiac pathology (predominantly lung nodules) requiring further evaluation. Follow-up was not as complete as in the lung cancer screening study above, but the expected incidence of actual lung cancer in these individuals would be expected to be much lower than the 1.3 percent of smokers seen in the lung cancer targeted screening population.",
"   </p>",
"   <p>",
"    Similarly, a study of coronary CT screening performed in a predominantly healthy, middle-aged population found 91 incidental noncoronary CT findings in 79 patients (8 percent), with a variety of organs involved including lungs, bone, liver, non-coronary-artery cardiovascular, gastrointestinal, and other soft tissue. No cancers were detected, but one-third of the lesions required substantial further evaluation, and several prompted an invasive procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 1192 patients who underwent screening FBCT found that 86 percent had at least one abnormal finding described in the report of the CT (average of 2.8 findings per patient) and that further evaluation was recommended for 37 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/22\">",
"     22",
"    </a>",
"    ]. The study did not examine how many of these abnormalities were false positives or how these evaluations affected outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adverse effects associated with true positives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can also be harmed by findings of actual disease on FBCT, if those findings do not, on balance, lead to improved patient outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Overdiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the risks of total body imaging is overdiagnosis: the diagnosis of conditions that would not have become clinically significant if not detected by screening [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/23\">",
"     23",
"    </a>",
"    ]. Although once believed to be rare, several autopsy studies, and experience with different forms of screening, suggest that the potential for overdiagnosis is vast, even for lung cancer, which is often assumed to be uniformly lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. Although this may be the most serious potential harm from total body imaging, the public is largely unaware of this side effect [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Harm from interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, in order for a screening test to be of benefit, disease must be detected during an asymptomatic phase during which interventions improve outcomes compared with what would occur if diagnosis had been delayed until the patient was symptomatic.",
"   </p>",
"   <p>",
"    For conditions that do not have good therapies (for instance, that are frequently fatal even when found preclinically), early diagnosis may not improve outcomes and could actually lead to worse outcomes; patients detected on screening might undergo risky diagnostic and therapeutic interventions earlier in the course of disease leading to earlier complications without resultant benefit. As an example, if patients found on FBCT to have asymptomatic hepatoma did not have better outcomes after interventions for hepatoma than patients who were detected later in the course of disease, then those found on screening might be harmed by chemotherapy or attempted curative surgery. There are no data from controlled trials that address this issue with FBCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Future insurability",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, health insurance has become increasingly difficult for many to afford. Most new policies, particularly those not written for large groups, seek to exclude patients with known health conditions. Even in asymptomatic individuals, conditions uncovered with total body imaging may have implications for future insurability.",
"   </p>",
"   <p>",
"    These concerns are similar to those faced by patients considering genetic screening. The effect of subclinical disease testing on insurability is not well known, but decreased insurability is a potential adverse consequence worthy of consideration by clinicians and patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective radiation doses from CT imaging vary with equipment, patient size, and body part(s) imaged. Facilities performing CT imaging for \"screening\" purposes often adjust radiation doses to levels 20 to 50 percent below typical diagnostic studies to market so called \"low-dose CT scans.\"",
"   </p>",
"   <p>",
"    While the effective dose for diagnostic CT procedures has decreased with advances in technology to between 1 and 10 mSv, a FBCT with an effective dose of 10 mSv would equal the radiation from approximately 500 chest x-rays (PA film of 0.02 mSv) or that sustained during 3.3 years of natural background radiation (US average).",
"   </p>",
"   <p>",
"    A report that estimated the effective dose of radiation from FBCT at 12 mSv assessed what the associated cancer risk would be by looking at rates of cancer seen in the lowest dose category of Japanese atomic bomb survivors who were exposed to 5 to 50 mSv (mean 20 mSv) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/30\">",
"     30",
"    </a>",
"    ]. Based on data from these atomic bomb survivors, the authors estimated that an adult undergoing a single FBCT at age 45 would have an attributable lifetime cancer mortality risk of 0.08 percent (1 in 1250). For a 45-year-old adult who undergoes annual FBCT screening until age 75 (30 examinations), the authors estimated an attributable lifetime cancer mortality risk of 1.9 percent (approximately 1 in 50). Furthermore, follow-up evaluation of incidentally found lesions would result in additional radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this added risk to an individual is relatively small compared with the estimated 20 percent lifetime risk of cancer in general, it must be weighed against the lack of known mortality benefit with FBCT and could have significant implications for large populations of screened individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/31\">",
"     31",
"    </a>",
"    ]. A review concluded that all estimates suggest important population increases in cancer incidence and mortality for individuals exposed before age 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/32\">",
"     32",
"    </a>",
"    ]. Details of radiation-related risk and clinical features of radiation injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Psychological effects of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anxiety and inconvenience generated by a suspicious finding as well as by the subsequent diagnostic work-up is often underestimated. As an example, a study found that three months after a high-suspicion but false-positive mammography for breast cancer, 47 percent of women experienced persistent mammography-related anxiety, 41 percent experienced ongoing worries about breast cancer, 26 percent noted effects on their daily moods, and 17 percent noted effects on their daily function [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether similar anxieties follow false-positive CT screening procedures has not been studied, but the suspicion of cancer or heart disease is likely to generate some degree of apprehension. Increased health care and utilization have been found after false-positive mammograms for breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In a systematic review of the psychological impact of predicting individuals' risks of illness, receiving a positive test result was associated in the short term with anxiety, depression, poorer perceptions of health, and psychological distress [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized trial of coronary CT imaging showed no effects on overall anxiety or depression associated with the knowledge of coronary calcification score; however, this trial did not report effects within the subgroup of patients found to have high calcification scores who might have been expected to have increased psychological symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     BENEFITS OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from the potential benefit of detecting asymptomatic disease at a time when early intervention might improve outcomes, normal findings will give most people a sense of reassurance about their risk of disease.",
"   </p>",
"   <p>",
"    The overall health impact of reassurance is not well understood in terms of quality of life effects. It is possible that false-negative results on FBCT might delay diagnosis or that true-negative results might adversely impact healthy behaviors.",
"   </p>",
"   <p>",
"    The act of undergoing screening could potentially lead to changes in lifestyle by causing patients to focus on high-risk behaviors. Patients who were smokers and participated in a study of CT screening for lung cancer reported a higher rate of smoking abstinence one year after screening (14 percent) than would have been expected in comparison with other cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Frequency of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before a screening test can be recommended, there must be evidence of continued effectiveness over time. There are insufficient data on this issue for FBCT. Also, if FBCT is to be recommended, the optimal screening frequency is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Issues related to self-referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of sufficient, mature clinical evidence about the usefulness of FBCT scanning, and given the potential theoretical harms, self-referral for this unproven technology creates a dilemma for providers faced with a patient seeking guidance on the results of a scan.",
"   </p>",
"   <p>",
"    Although in the case of coronary CT, most scanners are now associated with post-scan counseling by an ancillary healthcare provider (usually a nurse educator), treatment recommendations are limited by the absence of credible evidence regarding how the presence, absence, or extent of calcification changes one's management of cardiovascular risk factors. Patients receive this information outside of an established relationship with a primary care provider and, therefore, often lack the context of a baseline risk assessment based upon validly measured risk factors.",
"   </p>",
"   <p>",
"    Primary providers, who may not have ordered or discussed the study with the patient before it was done, are expected by the patient to provide management recommendations and education without clear supporting evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Technology assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technology assessment is a formal method to determine the effectiveness of a diagnostic technology compared with current alternatives. Most diagnostic technologies that become a part of standard medical practice do not undergo formal technology assessment.",
"   </p>",
"   <p>",
"    Even in the setting of demonstrable incremental effectiveness, the further question of whether it is worth it (ie, cost-effectiveness) is also uncommonly addressed. In an age of direct-to-consumer marketing, it is important for the clinician to understand the process of how new diagnostic technologies are approved for clinical use since, unlike medication approval, medical device approval is heavily weighted toward assessing safety rather than effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once approved, rapid deployment of new technology through aggressive marketing may promote a false sense of efficacy, thereby further encouraging its use and leading to a \"standard of care\" impression among the community that leads to excessive, inappropriate utilization. In the United States, although by law all medical devices are supposed to be assessed on both safety and effectiveness, the burden of device applications to the FDA (roughly 4000 per year) has led to a practice of approving devices through a more rapid approval process using the claim of \"substantial equivalence\" rather than through a premarket approval application, which requires substantially more clinical data (preferably randomized trials).",
"   </p>",
"   <p>",
"    Also, because of the challenges to keep the product-to-market time short (allowing patients to benefit earlier from medical advances, if efficacious) yet continue to ensure safety, the FDA can allow a device to reach the market sooner. This method relies on postmarketing surveillance and evaluation to determine the balance of risks and benefits. This practice is designed to identify uncommon but potentially serious device-related adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One concern with relying on post-marketing surveillance to assess safety is that it is not sensitive to minor adverse events, which when considering large populations would miss a substantial adverse event burden attributable to a test (as an example, a decrement in quality of life associated with increased worry from a questionable abnormality). When accumulated over large, healthy, screening populations even a very small decrement in quality of life for brief periods can have a substantial net negative effect. Such minor effects on individual patient-centered outcomes are typically not incorporated into diagnostic technology assessment.",
"   </p>",
"   <p>",
"    The standard of \"safe and effective\" to which the FDA is held for approving medical devices is different than the standard of \"reasonable and medically necessary\" to which, for example, the Centers for Medicare and Medicaid Services is held for the financing of medical devices and by which clinicians generally practice. Given the reliance on post-marketing data to determine the bare minimum of safety and effectiveness, the clinician is often faced with inadequate data to assess whether such a diagnostic test is either reasonable or necessary. In the absence of such data, the ethical obligation of the clinician is to counsel patients accordingly in such settings and to rely on executing medical judgment in a shared decision-making manner [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If such screening diagnostic technology gets advertised on a self-referral basis, thereby bypassing the provider-patient relationship, the benefits of rational, informed, shared decision making cannot be realized, and unreasonable, medically unnecessary testing will likely result [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS BY EXPERT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medical organizations that have studied and released position statements on the use of total body imaging oppose them. Such statements have been released by the Health Physics Society, the American College of Radiology, the American Association of Physicists in Medicine, and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) recommends against routine screening with electron beam CT for either the presence of severe coronary artery stenosis or the prediction of CHD in adults at low risk for CHD. The USPSTF found insufficient evidence to recommend for or against electron beam CT in adults at increased risk for CHD events [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/48\">",
"     48",
"    </a>",
"    ]. The USPSTF found insufficient evidence to recommend for or against lung cancer screening with CT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/49\">",
"     49",
"    </a>",
"    ]. The USPSTF clinical practice guidelines for screening for coronary heart disease and lung cancer screening, as well as other USPSTF guidelines, can be accessed through the website for the",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     Agency for Healthcare Research and Quality",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The FDA states that no evidence exists demonstrating that \"whole-body CT screening is effective in detecting any particular disease early enough for the disease to be managed, treated, or cured and advantageously spare a person at least some of the detriment associated with serious illness or premature death\" [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific arguments against the use of whole-body CT imaging among asymptomatic, low-to-moderate risk individuals include its high false-positive rate, length and lead-time bias, overdiagnosis, heightened anxiety, radiation exposure, false reassurance, and both the direct and indirect costs of the test [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16952/abstract/19,31,51,52\">",
"     19,31,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are limited data on the accuracy and cost-effectiveness of screening asymptomatic individuals with total body imaging. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening with FBCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data from the use of CT for lung cancer screening and for detection of coronary calcium suggest that total body imaging can be expected to have a very high ratio of false-positive findings to true-positive findings. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Extrapolation to other conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no data that total body imaging improves outcomes. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Benefits of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential harms of total body imaging include: false-positive results leading to unnecessary tests and procedures as well as psychological distress, true-positive results leading to overdiagnosis of disease and futile therapies, and individual and societal costs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risks of screening with FBCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of additional data from well-performed controlled trials of total body imaging, we recommend that low-risk asymptomatic individuals not undergo such screening (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening with FBCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As people self-refer for total body imaging, clinicians will be confronted with suspicious results on imaging without good data on their implications or the appropriate additional steps for diagnosis and management. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Issues related to self-referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/1\">",
"      Kolber CT, Zipp G, Glendinning D, Mitchell JJ. Patient expectations of full-body CT screening. AJR Am J Roentgenol 2007; 188:W297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/2\">",
"      Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004; 291:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/3\">",
"      Kalish GM, Bhargavan M, Sunshine JH, Forman HP. Self-referred whole-body imaging: where are we now? Radiology 2004; 233:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/4\">",
"      Eustace SJ, Nelson E. Whole body magnetic resonance imaging. BMJ 2004; 328:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/5\">",
"      Johnston C, Brennan S, Ford S, Eustace S. Whole body MR imaging: applications in oncology. Eur J Surg Oncol 2006; 32:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/6\">",
"      Hara AK, Johnson CD, MacCarty RL, Welch TJ. Incidental extracolonic findings at CT colonography. Radiology 2000; 215:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/7\">",
"      Rajapaksa RC, Macari M, Bini EJ. Prevalence and impact of extracolonic findings in patients undergoing CT colonography. J Clin Gastroenterol 2004; 38:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/8\">",
"      Yee J, Kumar NN, Godara S, et al. Extracolonic abnormalities discovered incidentally at CT colonography in a male population. Radiology 2005; 236:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/9\">",
"      Multicentre Aneurysm Screening Study Group. Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. BMJ 2002; 325:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/10\">",
"      Hunink MG, Gazelle GS. CT screening: a trade-off of risks, benefits, and costs. J Clin Invest 2003; 111:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/11\">",
"      Beinfeld MT, Wittenberg E, Gazelle GS. Cost-effectiveness of whole-body CT screening. Radiology 2005; 234:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/12\">",
"      Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003; 289:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/13\">",
"      O'Malley PG, Greenberg BA, Taylor AJ. Cost-effectiveness of using electron beam computed tomography to identify patients at risk for clinical coronary artery disease. Am Heart J 2004; 148:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/14\">",
"      Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol 2005; 46:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/15\">",
"      Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003; 226:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/16\">",
"      Mack MJ, Hazelrigg SR, Landreneau RJ, Acuff TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg 1993; 56:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/17\">",
"      Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992; 101:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/18\">",
"      Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screenings. Cancer 2001; 92:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/19\">",
"      Swensen SJ, Jett JR, Sloan JA, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002; 165:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/20\">",
"      Swensen SJ. Screening for cancer with computed tomography. BMJ 2003; 326:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/21\">",
"      Elgin EE, O'Malley PG, Feuerstein I, Taylor AJ. Frequency and severity of \"incidentalomas\" encountered during electron beam computed tomography for coronary calcium in middle-aged army personnel. Am J Cardiol 2002; 90:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/22\">",
"      Furtado CD, Aguirre DA, Sirlin CB, et al. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology 2005; 237:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/23\">",
"      Black WC. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 2000; 92:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/24\">",
"      Chan CK, Wells CK, McFarlane MJ, Feinstein AR. More lung cancer but better survival. Implications of secular trends in \"necropsy surprise\" rates. Chest 1989; 96:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/25\">",
"      Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/26\">",
"      Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/27\">",
"      Aoki T, Nakata H, Watanabe H, et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 2000; 174:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/28\">",
"      Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002; 346:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/29\">",
"      Schwartz LM, Woloshin S, Sox HC, et al. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ 2000; 320:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/30\">",
"      Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004; 232:735.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. FDA cites drawbacks of whole body CT scanning. FDA Patient Safety News 2002. Available at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/ (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/32\">",
"      Prokop M. Cancer screening with CT: dose controversy. Eur Radiol 2005; 15 Suppl 4:D55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/33\">",
"      Lerman C, Trock B, Rimer BK, et al. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 1991; 114:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/34\">",
"      Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998; 338:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/35\">",
"      Fletcher SW. False-positive screening mammograms: good news, but more to do. Ann Intern Med 1999; 131:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/36\">",
"      Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ 1996; 312:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/37\">",
"      Shaw C, Abrams K, Marteau TM. Psychological impact of predicting individuals' risks of illness: a systematic review. Soc Sci Med 1999; 49:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/38\">",
"      O'Malley PG, Feuerstein IM, Taylor AJ. Impact of electron beam tomography, with or without case management, on motivation, behavioral change, and cardiovascular risk profile: a randomized controlled trial. JAMA 2003; 289:2215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/39\">",
"      Cox LS, Clark MM, Jett JR, et al. Change in smoking status after spiral chest computed tomography scan screening. Cancer 2003; 98:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/40\">",
"      Maisel WH. Medical device regulation: an introduction for the practicing physician. Ann Intern Med 2004; 140:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/41\">",
"      Food and Drug Administration, HHS. Postmarket surveillance. Final rule. Fed Regist 2002; 67:38878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/42\">",
"      Smith JJ, Berlin L. Informed consent when using medical devices for indications not approved by the Food and Drug Administration. AJR Am J Roentgenol 1999; 173:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/43\">",
"      Taylor AJ, O'Malley PG. Self-referral of patients for electron-beam computed tomography to screen for coronary artery disease. N Engl J Med 1998; 339:2018.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of Physicists in Medicine. CT body scanning not scientifically justified for asymptomatic patients 2004. Available at: www.aapm.org/announcements/CT.html (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     American College of Radiology. ACR statement on CT screening exams 2002. Available at: file://www.acr.org/MainMenuCategories/media_room/FeaturedCategories/PressReleases/Archive/ACRStatementonCTScreeningExamsDoc15.aspx (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     Health Physics Society. Whole-body computerized tomography for screening should not be performed 2003. Available at: hps.org/documents/CTPosStm.pdf (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/47\">",
"      O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 2000; 36:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/48\">",
"      U.S. Preventive Services Task Force. Screening for coronary heart disease: recommendation statement. Ann Intern Med 2004; 140:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/49\">",
"      U.S. Preventive Services Task Force. Lung cancer screening: recommendation statement. Ann Intern Med 2004; 140:738.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration. Whole body scanning using computed tomography (CT). How does the FDA regulate CT systems? 2004. Available at: file://www.fda.gov/Radiation-EmittingProducts/RadiationEmittingProductsandProcedures/MedicalImaging/MedicalX-Rays/ucm115331.htm (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/51\">",
"      Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology screening tests. N Engl J Med 2002; 346:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16952/abstract/52\">",
"      Black WC. Invited commentary. Radiographics 2002; 22:1536.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2755 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16952=[""].join("\n");
var outline_f16_35_16952=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCREENING WITH FBCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Colon cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extrapolation to other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Costs of screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RISKS OF SCREENING WITH FBCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adverse effects associated with false positives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adverse effects associated with true positives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Overdiagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Harm from interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Future insurability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Psychological effects of screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      BENEFITS OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Frequency of screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Issues related to self-referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Technology assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RECOMMENDATIONS BY EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36632?source=related_link\">",
"      Computed tomographic colonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_35_16953="Tinea pedis interdigital maceration";
var content_f16_35_16953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76067%7EPC%2F80436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76067%7EPC%2F80436&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea pedis with interdigital maceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and white, macerated skin are present between the toes in this patient with tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interdigital tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fissuring and maceration are present between the toes in this case of interdigital chronic tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16953=[""].join("\n");
var outline_f16_35_16953=null;
var title_f16_35_16954="HIV and women";
var content_f16_35_16954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HIV and women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/35/16954/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16954/contributors\">",
"     Lisa Hirschhorn, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/35/16954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16954/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/35/16954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/35/16954/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/35/16954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women represent one of the fastest growing populations infected with the human immunodeficiency virus (HIV) in the United States. While many of the clinical manifestations of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    in women are similar to men, there remain significant gender-based differences in the disease. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Differences in viral load early in infection",
"     </li>",
"     <li>",
"      Differences in selected opportunistic infections",
"     </li>",
"     <li>",
"      Difference in selected ARV-related toxicities and side effects",
"     </li>",
"     <li>",
"      A number of female-specific complications",
"     </li>",
"     <li>",
"      Issues related to HIV and pregnancy",
"     </li>",
"     <li>",
"      The psychosocial impact and the environment in which",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      occurs in women",
"     </li>",
"     <li>",
"      Access to and receipt of quality care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, clinical complications, and natural history of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    in women, and the care of nonpregnant HIV-infected women in the United States, will be reviewed here. HIV in pregnant women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence of HIV in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the early 1980s, the percent of AIDS cases accounted for by women in the United States has grown annually according to reports from the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/1\">",
"     1",
"    </a>",
"    ]. In 1985, 7 percent of AIDS cases were in adult women compared to 27 percent in 2007. As of December 2007, 198,544 AIDS cases had been reported in girls and women.",
"   </p>",
"   <p>",
"    Since the initial reports of AIDS in women, women from minority populations have been disproportionately represented. In 1997, rates in African American and Latina women were 20 and 7 times higher than in Caucasians (58.8 and 21.5, respectively, versus 3.0 per 100,000) with persistence of over-representation of minorities in both AIDS and newly reported HIV infections through 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In 2007, 83 percent of women diagnosed with AIDS were from communities of color, with 65 percent in non-Hispanic Blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the women with AIDS come from communities with a history of poor access to health care and with high rates of poverty, unstable housing, domestic violence, and substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/4\">",
"     4",
"    </a>",
"    ]. In one study in which 291 women with AIDS were interviewed between 1990 and 1992, 90 percent were unemployed, 83 percent had an annual income under $10,000, and approximately half had at least one child under the age of 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/5\">",
"     5",
"    </a>",
"    ]. Even 15 years later, HIV in women is still disproportionately represented in poor disadvantaged communities. There are limited data on the natural history of AIDS in women independent of these social and economic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, increasing numbers of women with AIDS are from rural and smaller metropolitan areas rather than large urban centers, communities that often face additional barriers to access and retention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for HIV acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other aspects of the epidemiology of HIV are also changing for women. Heterosexual contact is the most common reported risk factor for women, overtaking injection drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/3\">",
"     3",
"    </a>",
"    ]. A number of risk factors for acquisition are shared between men and women, including presence of ulcerative sexually transmitted infections, higher viral loads, and unprotected sexual intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that during the normal menstrual cycle, there is a period lasting approximately 7 to 10 days when innate, humoral, and cell-mediated immunity are suppressed by estradiol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone, enhancing the potential for acquisition of HIV by women; this hypothesis requires further exploration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/8\">",
"     8",
"    </a>",
"    ]. However, even if this may represent a period of higher risk, primary prevention efforts for women should continue to emphasize the need for consistent adherence to safer sex practices regardless of timing in the menstrual cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The understanding of the presence and extent of differences between the sexes in the natural history of HIV and the progression to AIDS continues to evolve. Early in the epidemic, a number of studies reported higher mortality and increased progression of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    in women compared with men. However, more careful analyses incorporating other potential factors such as HIV risk, age, and the AIDS-defining condition showed that these differences were largely explained by decreased access to quality care and treatment rather than representing a more aggressive disease progression in women on biological grounds [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Women who receive care in more experienced clinics survive longer than women cared for by less experienced clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/13\">",
"     13",
"    </a>",
"    ]. However, even among established HIV clinics and adjusting for insurance rates, race and transmission, women were still less likely to be on HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/14\">",
"     14",
"    </a>",
"    ]. Delay in diagnosis is also common, with one-third of women either presenting with AIDS at the time of their HIV diagnosis or progressing to AIDS within the first 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1996, declines in AIDS-related mortality began to be noted, attributed to improved HIV treatment with highly active antiretroviral therapy (HAART) and improved prevention of opportunistic infections (OIs). However, the decline in AIDS-related mortality for women was less dramatic and lagged behind that of men (10 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/15\">",
"     15",
"    </a>",
"    ], although the rates of survival three years after diagnosis are now similar for men and women overall [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/3\">",
"     3",
"    </a>",
"    ]. This delay in benefit has not been fully explained but, based upon the experiences earlier in the epidemic, is probably in part related to decreased access to or use of quality care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ], although ongoing work to understand the potential impact of biological differences continues. In contrast, emerging data from resource-limited settings suggests the opposite, with men having higher adjusted mortality rates than women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/18\">",
"     18",
"    </a>",
"    ]. Regardless, AIDS remains a leading cause of death in women from minority populations, and mortality rates among women of color diagnosed with HIV in 2007 remained higher than white women diagnosed in the same year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Depression and HIV disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression may be a contributory factor for HIV progression in women. In a prospective longitudinal cohort study of 765 HIV seropositive women in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/19\">",
"     19",
"    </a>",
"    ], those with chronic depressive symptoms were twice as likely to die as those with mild or no depressive symptoms, after controlling for clinical features and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACCESS TO QUALITY OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of barriers to care exist for women, ranging from concrete needs (childcare, transportation, housing lack of insurance) to psychological and social barriers (fear of disclosure, denial, and cultural mistrust of the healthcare system) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, a large percentage of women with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    provide primary care for family members who may include children or other patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    Thus, it is not uncommon for women to compromise their own care to provide care for others. Finally, there has been growing recognition of high rates of intimate partner and other violence against women, which may prevent HIV-infected women from accessing or remaining in medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite efforts to increase access and utilization of care, HIV-infected women continue to receive lower quality of care, even after adjusting for potential confounders, including race and HIV transmission risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/6,14,17,22\">",
"     6,14,17,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GENDER-RELATED BIOLOGICAL DIFFERENCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Viral load differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;While gender-based differences in access and receipt of care exist, biological differences also exist. A natural cohort study of 812 specimens from 650 injection drug users (IDU) identified differences in viral load measurements between men and women; women had lower viral copies compared to men after controlling for CD4 counts (3365",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    versus 8907 by branched DNA assay and 45,416",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    versus 93,130 by reverse transcriptase polymerase chain reaction assay) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/23\">",
"     23",
"    </a>",
"    ]. The time to the development of AIDS was not different between the sexes. Another way to look at this is that women had a 1.6-fold increased risk of progressing to AIDS compared with men with the same viral load and CD4 cell count.",
"   </p>",
"   <p>",
"    Many other studies have also found this gender-based difference in viral loads, with no difference in overall mortality; the difference appears to be occurring primarily in the years following seroconversion. One group found significantly lower viral loads at seroconversion in women compared with men (15,103 versus 50,766",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    respectively) without differences in CD4 cell count. Initial viral load was a predictor of HIV progression for men but not for women, with women rapid progressors having a median initial viral load of 17,149 compared with 77,822 for male progressors.",
"   </p>",
"   <p>",
"    A review of 9 cross-sectional and 4 longitudinal studies, which included viral load measurements in males and females, women had greater than twofold lower levels of HIV RNA than men, despite controlling for CD4 counts and time from seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/24\">",
"     24",
"    </a>",
"    ]. Although the initial level of HIV RNA was lower in women than in men, the rates of disease progression appear similar [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of primary HIV infection are similar in women and men. However, a study looking at sex-based differences at the time of seroconversion from Kenya found that women were more likely to be infected with diverse variants of HIV, even at the time of initial infection in comparison to men [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/26\">",
"     26",
"    </a>",
"    ]. Viral isolates were obtained during primary HIV infection and prior to seroconversion in both men and women. Both groups had similar frequency of sexual intercourse and sexually transmitted diseases. The difference was quite striking; 20 of 32 women had multiple variants of the virus compared to 0 of 10 for the men, although the clinical significance of this finding and impact on viral load at seroconversion remains unknown at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS IN WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis jirovecii pneumonia is the most common AIDS-defining infection in women and men, and advanced immunosuppression (CD4 cell count",
"    <span class=\"nowrap\">",
"     &lt;200/mm3)",
"    </span>",
"    is the most common AIDS-defining condition in both populations. Rates of other OIs do not differ with a few exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/27\">",
"     27",
"    </a>",
"    ]. Kaposi's sarcoma (KS) remains more common in men in the United States, probably related to a higher prevalence of coinfection with the etiologic agent, human herpesvirus type 8. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=see_link\">",
"     \"Disease associations of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study of 107 patients with KS in a large municipal hospital, 11 percent were women; birth outside of the United States was a significant risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/28\">",
"     28",
"    </a>",
"    ]. Women with KS tended to present with more advanced and extensive disease, possibly related to delay in diagnosis.",
"   </p>",
"   <p>",
"    A number of cohort studies have reported a higher incidence of Candida esophagitis in HIV-infected women. Some studies have also found increased rates of bacterial infections and herpes simplex virus (HSV) infections in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/12,22\">",
"     12,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For many women, gynecologic complaints are the initial manifestation of",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    These conditions, which also exist in uninfected women, can occur with higher frequency and severity in women with HIV.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Candida vaginitis",
"     </li>",
"     <li>",
"      Abnormal cervical cytology",
"     </li>",
"     <li>",
"      Pelvic inflammatory disease",
"     </li>",
"     <li>",
"      Genital ulcer disease (eg, HSV, chancroid, syphilis, idiopathic)",
"     </li>",
"     <li>",
"      Menstrual disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of these conditions, including Candida vaginitis and abnormal cervical cytology, occur at increased rates; others, including HSV and other genital ulcer diseases, may be more difficult to treat.",
"   </p>",
"   <p>",
"    Women with HIV should receive a pelvic examination with appropriate studies including KOH and normal saline examination of any vaginal discharge, testing for chlamydia and gonococcal infections, regular Papanicolaou smears, and other studies as indicated by the complaints and clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Candida vaginitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent Candida vaginitis (at least four episodes in one year) may be the initial complaint of women with HIV and is the most common HIV-related gynecological symptom in women. It is also a common condition in women without HIV infection. One prospective study found a higher incidence and persistence but not severity of Candida vaginitis among HIV-infected women compared to women at risk for HIV who did not have the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is generally topical unless the infection does not respond or recurs frequently. Systemic treatment and suppression with imidazoles are effective, although long-term use can lead to colonization with resistant Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/30\">",
"     30",
"    </a>",
"    ]. One study in 323 HIV-infected women with CD4 counts",
"    <span class=\"nowrap\">",
"     &lt;300/mm3",
"    </span>",
"    found that intermittent suppression with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 mg PO once weekly) was effective as suppressive therapy without a high risk of resistance (under 5 percent in both the treatment group and control patients not receiving therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/31\">",
"     31",
"    </a>",
"    ]. Weekly fluconazole prevented both vaginal and oropharyngeal candidiasis but not esophageal candidiasis. However, the need for preventive therapy has declined with the advent of more potent and durable ART regimens.",
"   </p>",
"   <p>",
"    Other reasons for apparent treatment failure or breakthrough include a second etiologic agent (see below) and noninfectious conditions. These other diagnoses can be made after appropriate pelvic examination and cultures of vaginal and cervical discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bacterial vaginosis, genital ulcers, and pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other gynecologic infections also occur in women with HIV.",
"   </p>",
"   <p>",
"    Bacterial vaginosis may result in recurrent vaginal discharge. A prospective cohort study conducted over a five-year period found that bacterial vaginosis was both more prevalent and more persistent among HIV-infected women compared to those without HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/32\">",
"     32",
"    </a>",
"    ]. HIV-infected women with CD4 cell counts",
"    <span class=\"nowrap\">",
"     &lt;200/microL",
"    </span>",
"    were more likely to have both persistent and severe bacterial vaginosis than those with CD4 counts",
"    <span class=\"nowrap\">",
"     &gt;500/microL.",
"    </span>",
"    Standard treatment regimens for HIV-infected patients with bacterial vaginosis are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .) Bacterial vaginosis may also be a risk factor for HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, genital HSV infections are increased in frequency and severity in women with HIV. Treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    and suppressive therapy for women with frequent recurrences is recommended.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     Valacyclovir",
"    </a>",
"    is also active against genital HSV; however, reports of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in patients with advanced AIDS suggest caution in its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genital ulcers can be caused by infectious agents other than HSV or may be idiopathic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Chancroid (Haemophilus ducreyi infection) is especially common in women from developing countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=see_link\">",
"     \"Approach to the patient with genital ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=see_link\">",
"     \"Chancroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies of pelvic inflammatory disease (PID) in women with HIV have found increased risk of complications while others have not. Early in the epidemic, one study reported that HIV-positive women with pelvic inflammatory disease (PID) presented with fewer signs of acute infection, were more likely to have a delayed response to treatment, and more frequently required surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/37\">",
"     37",
"    </a>",
"    ]. A second survey did not show any increased risk for complications but did document more disease severity on presentation and longer hospital stays for HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/38\">",
"     38",
"    </a>",
"    ]. However, a third prospective study of 207 women with PID (44 with HIV infection and 163 without) found no differences between HIV-infected and uninfected women in severity of symptoms or response to therapy, regardless of CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/39\">",
"     39",
"    </a>",
"    ]. Current recommendations are to hospitalize HIV-infected women with PID and to use standard therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to respond, especially in patients with advanced HIV, should prompt a change in treatment, ultrasonographic evaluation for tuboovarian abscess (TOA), and consideration of surgical intervention. As an example, in one study of 133 Kenyan women with PID verified by laparoscopy, the incidence of TOA was significantly higher in HIV-positive women (odds ratio 2.8) and was twice as frequent among HIV-positive women in whom the CD4 cell count was &lt;14 percent (55 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ABNORMAL CERVICAL CYTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased risk for low and high-grade squamous intraepithelial lesions (LSIL and HSIL), atypia (ASCUS), and carcinoma in women with HIV infection was first described early in the epidemic. As in women without HIV infection, high-risk types HPV-16 and HPV-18 are highly associated with abnormal cervical smears. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in risk is related to the degree of immunosuppression (CD4 cell count), coinfection with moderate and high-risk human papilloma virus (HPV) genotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], and cutaneous anergy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study prospectively evaluated a cohort of 328 HIV-infected women and 325 epidemiologically similar HIV-negative women without evidence of SIL by Pap smear or colposcopy for the development of SIL over a three-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/46\">",
"     46",
"    </a>",
"    ]. The HIV-infected patients were significantly more likely to develop SIL compared to the uninfected women (8.3 versus 1.8 cases per 100 person-years); 91 percent of these lesions were LSIL. None of the patients in either group developed cervical cancer during the follow-up period. Persistent HPV DNA, evidence of infection with multiple HPV types, and younger age were also associated with the appearance of SIL in a multivariate analysis.",
"   </p>",
"   <p>",
"    The strong association between HIV infection and human papillomavirus (HPV) infection increases with progressive immunosuppression and higher plasma viral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/43,47-49\">",
"     43,47-49",
"    </a>",
"    ]. In one report, HIV-positive women with a CD4 count less than",
"    <span class=\"nowrap\">",
"     200/microL",
"    </span>",
"    were at the highest risk of HPV infection, followed by women with a CD4 count greater than",
"    <span class=\"nowrap\">",
"     200/microL",
"    </span>",
"    and an HIV RNA load greater than 20,000",
"    <span class=\"nowrap\">",
"     copies/mL;",
"    </span>",
"    women with a CD4 count greater than",
"    <span class=\"nowrap\">",
"     200/microL",
"    </span>",
"    and an HIV RNA load less than 20,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were at lowest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/48\">",
"     48",
"    </a>",
"    ]. The association between advancing immunosuppression and risk for cervical disease may be related to decreased rates of HPV clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, there is a low risk of cytologic abnormalities in HIV-infected women with relatively preserved CD4 counts who test negative for HPV. Participants in the Women's Interagency HIV Study (WIHS) included 855 HIV-infected patients (mean age, 36 years) and 343 HIV-seronegative patients (mean age, 34 years) who had normal cervical cytology at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/51\">",
"     51",
"    </a>",
"    ]. The participants underwent semi-annual examinations that included cytologic evaluation. The study results were significant for the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At three years of follow-up, 29 percent of HIV-infected patients with a CD4+ T lymphocyte count &lt;200 cells, and 14 percent of those with CD4+ T lymphocyte counts ranging from 200 to 500 cells, had onset of SIL.",
"     </li>",
"     <li>",
"      HIV-infected patients with CD4+ T lymphocyte counts greater than 500 cells continued to have low rates of SIL that were comparable to HIV-seronegative women (6 versus 5 percent).",
"     </li>",
"     <li>",
"      Similarly, in a prospective study of a separate subset of women from the WIHS cohort, rates of HSIL detection through semi-annual cytological testing over five years were comparably low among 369 HIV-infected women (mean age 34 years, and 56 percent with CD4 cell count &gt;500",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      and 255 HIV-uninfected women (mean age 30 years) who had initially tested negative for oncogenic HPV at enrollment (0.4 and 0.3 percent cumulative incidence, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/52\">",
"       52",
"      </a>",
"      ]. One limitation of this study is that women who underwent treatment for cervical abnormalities were censored and thus not included in the incidence analysis, which may result in an underestimate of the incidence of HPV-related cervical atypia. However, the proportion of women censored appeared similar in both groups. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, screening procedures used for HIV-seronegative women who are 30 years or older and have normal cytology and negative HPV screening tests at baseline may be applicable to HIV-infected patients with CD4+ T lymphocyte counts greater than 500 cells who have no history of abnormal cytology, HPV coinfection, or other risk factors for cervical cancer; however, no change has been recommended in the most recent United States Public Health Service guidelines. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cervical neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with HIV are also more likely to present with multifocal disease and to progress more rapidly to cervical cancer. In addition, neoplasia is more likely to recur after treatment in these women, particularly as their CD4 cell counts decline [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/53\">",
"     53",
"    </a>",
"    ]. One study found that cervical neoplasia was the leading indication for hysterectomy in HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prevalence study in HIV-infected patients also found that high-risk HPV types, other than HPV-16 and HPV-18, are often found in this patient population and are frequently associated with abnormal cervical cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/55\">",
"     55",
"    </a>",
"    ]. Types most commonly associated with high-grade lesions were HPV-52 and HPV-58. HIV-infected women who are not infected with high-risk HPV types do not appear to have a higher risk of cervical intraepithelial neoplasia grade 2 or worse than HIV-uninfected women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Effect of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting study results as to whether ART has any impact on the risk and natural history of ASCUS, LSIL, and HSIL, and carcinoma in women with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Viral suppression secondary to ART use has been associated with a reduced burden of HPV infections and more rapid clearance of oncogenic HPV-positive cervical lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/60\">",
"     60",
"    </a>",
"    ]. However, the",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    Cancer Match Study (1980 to 2007) demonstrated that the proportion of cervical cancers among women with AIDS has increased from the pretreatment era to the ART era [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/59\">",
"     59",
"    </a>",
"    ]. Furthermore, among females without AIDS, cervical cancer incidence was higher than other cancers that were evaluated in this study (eg, lymphoma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since HIV-infected women have a much higher risk of HPV infection and cervical cancer than do HIV uninfected women, cervical screening is of paramount importance worldwide. Although early studies reported that Papanicolaou smears had low sensitivity for detection of cervical lesions, subsequent data have shown similar performance as in HIV-negative women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. However, even mildly abnormal cytology is a potential sign of cervical neoplasia and an indication for colposcopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to cervical screening in uninfected women differs from that among HIV-infected women. In HIV-seronegative women, guidelines for cervical cancer screening include cervical cytology and HPV testing in women 30 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/64\">",
"     64",
"    </a>",
"    ]. According to these guidelines, women with normal cervical cytology who test positive for oncogenic HPV types should be rescreened in one year, while those who are negative can be rescreened in five years. However, HPV testing is not currently recommended by the United States Public Health Service as part of cervical screening in HIV-infected women. Current guidelines recommend two cervical cytology screens at six-month intervals in the first year following HIV diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/33,65\">",
"     33,65",
"    </a>",
"    ]. For those with normal examinations and low risk (no prior abnormal Papanicolaou smear, AIDS-defining condition, or HPV infection), annual follow-up suffices [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/66\">",
"     66",
"    </a>",
"    ]; more frequent examinations are recommended for women at higher risk.",
"   </p>",
"   <p>",
"    Colposcopy should be reserved for women with abnormal cytology, including ASCUS [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/63,67\">",
"     63,67",
"    </a>",
"    ]. The appropriate management of abnormal cervical cytology and neoplasia, including optimal ablative therapy, role of postablative treatment with topical agents, and timing and method of follow-up, is still largely unknown. However, close follow-up by a provider with experience in HIV-related cervical disease is essential.",
"   </p>",
"   <p>",
"    The potential role of HPV vaccines in preventing cervical neoplasia in HIV-positive women is an area of active investigation, although initial studies have found immunogenicity among HIV-positive men [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link&amp;anchor=H5968486#H5968486\">",
"     \"Recommendations for the use of human papillomavirus vaccines\", section on 'Immunosuppressed or immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     VULVAR AND PERIANAL PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected women are at greater risk for vulvar and perianal pathology compared with HIV-seronegative women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/69\">",
"     69",
"    </a>",
"    ]. As with cervical pathology, HPV infection and HIV status are associated with vulvovaginal and perianal lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of 1562 HIV-infected women and 469 women without HIV found an increased incidence of genital warts and vulvar intraepithelial neoplasia among those with HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/70\">",
"       70",
"      </a>",
"      ]. The administration of potent ART decreased the risk of developing these conditions.",
"     </li>",
"     <li>",
"      In another prospective study of annual anal cytologic screening among 715 HIV-infected women, 11 of 18 (61 percent) with poorly controlled HIV infection had high-grade anal intraepithelial neoplasia but only 1 of 20 (5 percent) with HIV viral suppression had high-grade anal intraepithelial neoplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monitoring and evaluation of vulvar pathology in HIV-infected women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=see_link\">",
"     \"Screening for cervical cancer in HIV infected women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MENSTRUAL ABNORMALITIES AND MENOPAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menstrual abnormalities, including early menopause, have been described in a number of women with HIV infection, but the rates and patterns are not well studied [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/72\">",
"     72",
"    </a>",
"    ]. One cohort study found no difference in menstrual patterns between 197 HIV-infected women and 189 HIV-negative controls [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amenorrhea in a woman with HIV requires a standard work-up for gynecologic and endocrine etiologies as well as a pregnancy test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the population with HIV infection ages, the number of women approaching and experiencing menopause is growing. The risk-benefit ratio of hormonal replacement for these women remains to be described, as well as potential pharmacologic interactions between protease inhibitors and estrogen replacement. At this time, the decision about hormonal replacement should be made individually after education and counseling of the woman and determination of risk factors for cardiac disease, osteoporosis, cancer, and other conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GENITAL TRACT SHEDDING OF HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have detected HIV-1 proviral DNA, cell-free RNA,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cell-associated RNA in the female genital tract with variable rates of detection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. In one study of 97 women, paired plasma and cervical lavage specimens were collected to determine the patterns and predictors of genital tract HIV RNA during a 36 month period [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/76\">",
"     76",
"    </a>",
"    ]. The strongest predictor of HIV RNA detection in cervicolavage fluid was a plasma viral load of more than 2.6 log (10)",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    effect of antiretroviral therapy on genital tract shedding of HIV has been an active area of investigation. Studies have demonstrated that genital tract shedding can still occur, even when plasma viral load is suppressed:",
"   </p>",
"   <p>",
"    In a cross-sectional study of 290 women, 15 percent had detectable HIV RNA in their cervical specimens despite the fact that all participants had an HIV RNA level of &lt;500",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study of 59 women who were followed longitudinally over a median of 12 visits, genital tract shedding of HIV was demonstrated at 9 percent of visits when plasma viral load was undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential risk factors in other studies for shedding of HIV in the genital tract may include HSV infection. The impact of these findings on HIV transmission from mother to child or to sex partners is yet unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection\", section on 'Immunosuppressed patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PRIMARY CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary care for HIV-infected women raises some special issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     HIV therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of antiretroviral therapy in women appears comparable, or with certain antiretrovirals, even superior, to the response in men [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After controlling for potential confounders, there were no significant sex differences in virologic, immunologic, or clinical outcomes after starting HAART in a large multicenter study [",
"      <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective, observational, multicenter study from Spain, 1885 men and 735 women were evaluated over a 12-month period after initiating ART with a nelfinavir-containing regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/84\">",
"       84",
"      </a>",
"      ]. In a multivariate analysis, women had a better overall immunologic and virologic response to ART than men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there are some differences in medication tolerability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/79,84\">",
"     79,84",
"    </a>",
"    ]. Data from a large urban clinic found that women were more likely to have side effects related to HIV therapy and so discontinue their medications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/85\">",
"     85",
"    </a>",
"    ]. HIV-infected women also have a higher incidence of rash in association with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    administration compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Higher rates of severe hepatotoxicity have also been described in pregnant women with CD4 counts &gt;250",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    who were taking nevirapine. A study of darunavir-ritonavir also observed higher rates of discontinuation for reasons other than virologic failure among women, although rates of adverse events among women and men staying in the study were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/83\">",
"     83",
"    </a>",
"    ]. These gender-based differences may reflect differences in pharmacokinetics due to body weight or drug metabolism, hormonal differences, or other factors.",
"   </p>",
"   <p>",
"    There is no clearly established gender difference in the frequency of lipodystrophy or diabetes as a consequence of antiretroviral therapy. However, some studies have found increased risk of fat accumulation versus lipoatrophy in women and decreased risk of hyperlipidemia compared with men [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/88\">",
"     88",
"    </a>",
"    ]. Women may also be at an increased risk of developing lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adherence is a major barrier to success with HAART for women and men. Most studies to date have not found a gender-based difference in adherence, but women may have higher rates of other factors that present barriers to successfully taking these regimens. These may include competing needs of other family members with HIV and other infections, fear of disclosure in their own household, side effects, and body changes related to the lipodystrophy syndrome. Adherence support programs should be designed to address the multiple challenges for women on HIV therapy.",
"   </p>",
"   <p>",
"    In recent guidelines for the treatment of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    by the International AIDS Society-USA and DHHS, there are no gender-specific differences in recommendations for the treatment of women with",
"    <span class=\"nowrap\">",
"     HIV/AIDS,",
"    </span>",
"    although consideration of changes in treatment guidelines based upon viral load in women early in disease is discussed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Exceptions are women of childbearing potential who require careful follow-up when given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , due to their suspected teratogenicity, liquid amprenavir, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    because of congenital malformations.",
"   </p>",
"   <p>",
"    There are no gender-based differences in recommendations for monitoring CD4 cell counts and plasma viral load or for the prevention and treatment of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    .) As noted above, there may be differences in viral load and these data may be used in the future to assign different viral load thresholds for initiating therapy in women. In addition, the higher threshold for viral load, when used as the sole indicator to start HAART, has made this difference less clinically significant than when earlier guidelines were in place [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/25\">",
"     25",
"    </a>",
"    ]. Updated guidelines from the DHHS are regularly released and available on the website",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/\">",
"     file://aidsinfo.nih.gov",
"    </a>",
"    . However, the acceptance and tolerance of treatment regimens may differ for women. Decisions about therapy should be made only after education and discussion between the patient and her provider with appropriate support and follow-up provided.",
"   </p>",
"   <p>",
"    When initiating HAART in women of childbearing age, a baseline pregnancy test should be performed, particularly if any category D medications are being prescribed (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Health maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The care of women with HIV infection must incorporate primary care into their state-of-the-art HIV care. As women survive longer with HIV, other comorbid conditions will increase with age. Furthermore, HIV infection and treatment may increase the risk of many of these conditions, including diabetes, cardiovascular disease, cognitive dysfunction, renal insufficiency, and osteoporosis.",
"   </p>",
"   <p>",
"    HIV-infection is variably associated with the risk of non-AIDS-defining malignancies. Higher rates of some cancers, such as lung and anal cancer, have been reported among HIV-infected individuals, whereas lower age-adjusted rates have been observed for other cancers, such as colon and breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/93\">",
"     93",
"    </a>",
"    ]. Whether these differences are related to differences in risk or rates of screening compared with HIV-negative population is not known at this time.",
"   </p>",
"   <p>",
"    Thus, close attention to screening for comorbidities, reducing their risk, and effectively managing them is critical to the care of the HIV-infected patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/94\">",
"     94",
"    </a>",
"    ]. Moreover, clinicians should recognize that not all complaints are necessarily HIV-related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The complex psychosocial needs of many women with HIV often requires a multidisciplinary team to address issues such as housing, substance abuse, and mental illness, either on-site or by linkage with other institutions or community-based organizations. One group found that case management significantly improved care and use of HIV therapies for individuals with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CHOICE OF CONTRACEPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of contraception for a woman with HIV is often complicated and must incorporate issues related to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Specific contraceptives and their efficacy in preventing pregnancy",
"     </li>",
"     <li>",
"      Prevention of transmission of HIV and other sexually transmitted diseases",
"     </li>",
"     <li>",
"      Drug interactions between certain antiretroviral agents and hormonal contraceptives",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Women should be counseled that HIV can be transmitted even when the HIV-infected person has a very low HIV viral load. Due to the risk of HIV and other STD transmission, a form of barrier contraception is always recommended. Other factors may also influence a woman's choice of contraception, including whether she has been able to disclose her HIV status, fear of domestic violence, and other medical conditions. The best practice is dual contraception with a hormonal agent to prevent pregnancy and condoms to reduce the transmission of the virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hormonal contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal contraceptives (eg, oral, injectable) are effective reversible agents for the prevention of pregnancy in women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;While reliability does not appear to be reduced by HIV infection, efficacy can be compromised by drug interactions between estrogen and certain antiretroviral agents and other medications commonly used in individuals with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/96\">",
"     96",
"    </a>",
"    ] including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-nucleoside reverse transcriptase inhibitors (specifically",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Protease inhibitors",
"     </li>",
"     <li>",
"      Other medications which may be needed to treat HIV-related complications",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       Rifampin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    pharmacokinetics were not affected by either oral",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"      norethindrone",
"     </a>",
"     /ethinyl",
"    </span>",
"    estradiol (Ortho Novum) or intramuscular depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (Depo-Provera) in a study of 20 HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/97\">",
"     97",
"    </a>",
"    ]. Although no known interactions with progesterone-based contraceptives have been described, providers are cautioned to check for new information as research continues. A number of online resources are available which provide up-to-date information on drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Effect on HIV disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting results have been published on the effects of hormonal contraception on HIV disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/98\">",
"     98",
"    </a>",
"    ]. In two large studies, hormonal contraception was associated with more rapid CD4 T-cell depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]; however, other smaller studies did not support these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. All of these trials were performed in women who were not taking ART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Susceptibility to HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past decade, there have been conflicting data on whether or not hormonal contraception may influence susceptibility to HIV acquisition. Several concerns regarding methodological issues have been raised regarding these observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/103\">",
"     103",
"    </a>",
"    ]. Study of this area is also difficult due to differences in sexual behaviors between users and non-users of hormonal contraception. In one study, hormonal contraceptive use was not associated with susceptibility to HIV infection. However, in the subgroup of women who were HSV seronegative, acquisition of HSV infection was associated with increased risk of HIV transmission. This finding has been seen in other cohorts and may represent a marker for unsafe sexual practices rather than an impact of hormonal contraception. This study highlights the need to examine HSV serostatus, and other potential confounders, in any further studies of contraceptive use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Intrauterine contraceptive device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intrauterine contraceptive device also provides effective contraception, and appears to be safe to use in HIV-infected patients. One large randomized controlled trial in Zambia, which compared the safety and effectiveness of a copper IUD versus hormonal contraception, demonstrated that only one patient developed pelvic inflammatory disease during the two-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/99\">",
"     99",
"    </a>",
"    ]. Furthermore, women assigned to the IUD arm were significantly less likely to become pregnant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"     \"Overview of contraception\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H27\">",
"     'Hormonal contraceptives'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Condoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of male condoms, although less efficacious for the prevention of pregnancy, has been proven to reduce transmission of HIV and other STDs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Acceptance of male condom use may be limited by fear of disclosure, refusal by the partner and many other issues. Although the data are limited, it is likely that the female condom, when used properly, has similar efficacy as the male condom and is attractive as a woman-controlled method [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/106\">",
"     106",
"    </a>",
"    ]. While cost, convenience and esthetics have limited widespread use of the female condom; however effective interventions to increase the use of barrier methods in women and men are increasingly available. The diaphragm and cervical cap are associated with a decreased risk of gonorrhea, Chlamydia and trichomonas infections, and PID [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Much of the protective effect is probably due to the concomitant use of spermicides, and no impact on HIV transmission has been consistently shown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Microbicides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal microbicides, which are also spermicidal, are an area of ongoing research. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     HIV AND PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since many women with HIV are diagnosed during pregnancy and women with HIV may choose to become pregnant, primary care providers should have a basic understanding of the current state of knowledge regarding HIV and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/109\">",
"     109",
"    </a>",
"    ]. In addition, a frank discussion about pregnancy plans is important when determining optimal ART management, as some drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    are teratogenic and therefore should not be used in women who are considering pregnancy or not willing to use effective contraception. Attainment of a stable, maximally suppressed viral load prior to conception is recommended for HIV-infected women who are on ART and considering pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/110\">",
"     110",
"    </a>",
"    ]. Resistance testing is recommended prior to ART initiation for all patients, and is particularly important for pregnant women and those considering pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Public Health Service Task Force guidelines for management of pregnant women with HIV contain some helpful information for preconceptual counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?16/35/16954/abstract/110\">",
"     110",
"    </a>",
"    ]. Most of the focus in this area has concerned transmission of HIV to the fetus and the effect of antiretroviral medications on the fetus.",
"   </p>",
"   <p>",
"    Less has been written about the outcome of pregnancy in HIV-infected women. What data exist are largely derived from observational or cohort studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30756391\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heterosexual contact is the most commonly reported risk factor for HIV acquisition women worldwide. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early in the epidemic, several studies reported higher mortality and increased progression of",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      in women compared with men. However, subsequent data demonstrated that these differences were largely explained by decreased access to care by women rather than greater disease progression compared to men. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain genital infections, such as candida vaginitis and herpes simplex virus, appear to be more persistent and severe in HIV-infected women than in HIV-uninfected patients, although some of these differences have been reduced in women on effective ART. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations in women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected women have an increased risk for cervical dysplasia and cervical cancer compared with HIV-seronegative women. Risk of severe cervical disease is related to the degree of immunosuppression (as measured by the CD4 cell count), response to ART, and coinfection with moderate and high-risk human papilloma virus genotypes. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Abnormal cervical cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of contraception for a woman with HIV is often complicated and must incorporate issues related to the prevention of transmission of HIV and other sexually transmitted diseases and to drug interactions with antiretroviral medications and future conception plans. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Choice of contraception'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2008; Vol 20, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Diagnoses of HIV/AIDS--32 States, 2000-2003. MMWR Morb Mortal Wkly Rep 2004; 53:1106.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2007; Vol 19, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/4\">",
"      Hader SL, Smith DK, Moore JS, Holmberg SD. HIV infection in women in the United States: status at the Millennium. JAMA 2001; 285:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/5\">",
"      Chu SY, Diaz T. Living situation of women with AIDS. J Acquir Immune Defic Syndr 1993; 6:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/6\">",
"      Zierler S, Krieger N. Reframing women's risk: social inequalities and HIV infection. Annu Rev Public Health 1997; 18:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/7\">",
"      Chersich MF, Rees HV. Vulnerability of women in southern Africa to infection with HIV: biological determinants and priority health sector interventions. AIDS 2008; 22 Suppl 4:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/8\">",
"      Wira CR, Fahey JV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008; 22:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/9\">",
"      Ellerbrock TV, Bush TJ, Chamberland ME, Oxtoby MJ. Epidemiology of women with AIDS in the United States, 1981 through 1990. A comparison with heterosexual men with AIDS. JAMA 1991; 265:2971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/10\">",
"      Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994; 272:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/11\">",
"      Hirschhorn LR. HIV infection in women: Is it different. AIDS Reader 1995; 5:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/12\">",
"      Cozzi Lepri A, Pezzotti P, Dorrucci M, et al. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. BMJ 1994; 309:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/13\">",
"      Laine C, Markson LE, McKee LJ, et al. The relationship of clinic experience with advanced HIV and survival of women with AIDS. AIDS 1998; 12:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/14\">",
"      Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Update: trends in AIDS incidence -- United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/16\">",
"      Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the united states. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr 2000; 25:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/17\">",
"      Hirschhorn LR, McInnes K, Landon BE, et al. Gender differences in quality of HIV care in Ryan White CARE Act-funded clinics. Womens Health Issues 2006; 16:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/18\">",
"      Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med 2012; 9:e1001304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/19\">",
"      Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA 2001; 285:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/20\">",
"      Rumptz MH, Tobias C, Rajabiun S, et al. Factors associated with engaging socially marginalized HIV-positive persons in primary care. AIDS Patient Care STDS 2007; 21 Suppl 1:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/21\">",
"      Gruskin L, Gange SJ, Celentano D, et al. Incidence of violence against HIV-infected and uninfected women: findings from the HIV Epidemiology Research (HER) study. J Urban Health 2002; 79:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/22\">",
"      Clark RA, Brandon W, Dumestre J, Pindaro C. Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. Clin Infect Dis 1993; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/23\">",
"      Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/24\">",
"      Gandhi M, Bacchetti P, Miotti P, et al. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002; 35:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/25\">",
"      Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/26\">",
"      Long EM, Martin HL Jr, Kreiss JK, et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/27\">",
"      Fleming PL, Ciesielski CA, Byers RH, et al. Gender differences in reported AIDS-indicative diagnoses. J Infect Dis 1993; 168:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/28\">",
"      Cooley TP, Hirschhorn LR, O'Keane JC. Kaposi's sarcoma in women with AIDS. AIDS 1996; 10:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/29\">",
"      Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003; 101:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/30\">",
"      Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/31\">",
"      Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/32\">",
"      Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol 2001; 98:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/33\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/34\">",
"      Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 2005; 192:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/35\">",
"      LaGuardia KD, White MH, Saigo PE, et al. Genital ulcer disease in women infected with human immunodeficiency virus. Am J Obstet Gynecol 1995; 172:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/36\">",
"      Risbud A, Chan-Tack K, Gadkari D, et al. The etiology of genital ulcer disease by multiplex polymerase chain reaction and relationship to HIV infection among patients attending sexually transmitted disease clinics in Pune, India. Sex Transm Dis 1999; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/37\">",
"      Korn AP, Landers DV, Green JR, Sweet RL. Pelvic inflammatory disease in human immunodeficiency virus-infected women. Obstet Gynecol 1993; 82:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/38\">",
"      Barbosa C, Macasaet M, Brockmann S, et al. Pelvic inflammatory disease and human immunodeficiency virus infection. Obstet Gynecol 1997; 89:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/39\">",
"      Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000; 95:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/40\">",
"      Cohen CR, Sinei S, Reilly M, et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J Infect Dis 1998; 178:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/41\">",
"      Duerr A, Kieke B, Warren D, et al. Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/42\">",
"      Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002; 186:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/43\">",
"      Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/44\">",
"      Mandelblatt JS, Kanetsky P, Eggert L, Gold K. Is HIV infection a cofactor for cervical squamous cell neoplasia? Cancer Epidemiol Biomarkers Prev 1999; 8:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/45\">",
"      Harris TG, Burk RD, Xue X, et al. Association of cutaneous anergy with human papillomavirus and cervical neoplasia in HIV-seropositive and seronegative women. AIDS 2007; 21:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/46\">",
"      Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/47\">",
"      Vernon SD, Holmes KK, Reeves WC. Human papillomavirus infection and associated disease in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/48\">",
"      Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/49\">",
"      Ahdieh L, Mu&ntilde;oz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/50\">",
"      Rowhani-Rahbar A, Hawes SE, Sow PS, et al. The impact of HIV status and type on the clearance of human papillomavirus infection among Senegalese women. J Infect Dis 2007; 196:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/51\">",
"      Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005; 293:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/52\">",
"      Keller MJ, Burk RD, Xie X, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA 2012; 308:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/53\">",
"      Maiman M, Fruchter RG, Guy L, et al. Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993; 71:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/54\">",
"      Massad LS, Evans C, Weber K, et al. Hysterectomy among women with HIV: indications and incidence. J Acquir Immune Defic Syndr 2007; 44:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/55\">",
"      Luque AE, Jabeen M, Messing S, et al. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis 2006; 194:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/56\">",
"      Taylor G, Wolff T, Khanna N, et al. Genital dysplasia in women infected with human immunodeficiency virus. J Am Board Fam Pract 2004; 17:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/57\">",
"      Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/58\">",
"      Xi LF, Kiviat NB. Cervical neoplasia and highly active antiretroviral therapy. J Natl Cancer Inst 2004; 96:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/59\">",
"      Shiels MS, Pfeiffer RM, Hall HI, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 2011; 305:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/60\">",
"      Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 2010; 201:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/61\">",
"      Anderson JR, Paramsothy P, Heilig C, et al. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis 2006; 42:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/62\">",
"      Wright TC Jr, Moscarelli RD, Dole P, et al. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/63\">",
"      Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection on atypical squamous cells of undetermined significance. Clin Infect Dis 2006; 42:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/64\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/65\">",
"      Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001; 111:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/66\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     El-Sadr W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical practice guideline no. 7. Rockville, MD: US Department of Health and Human Services, Public Health Service, 1994; AHCPR publication no. 94&ndash;0572.",
"    </li>",
"    <li>",
"     Wilkin T, Lee J, Goldstone S, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in HIV-infected men: primary results of the AIDS Malignancy Consortium Trial 052. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, 16-19 February 2010, San Francisco, U.S. Abstract 1015.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/69\">",
"      Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/70\">",
"      Massad LS, Silverberg MJ, Springer G, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004; 190:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/71\">",
"      Hou JY, Smotkin D, Grossberg R, et al. High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer. J Acquir Immune Defic Syndr 2012; 60:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/72\">",
"      Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis 2005; 41:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/73\">",
"      Ellerbrock TV, Wright TC, Bush TJ, et al. Characteristics of menstruation in women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/74\">",
"      Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/75\">",
"      Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/76\">",
"      Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006; 42:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/77\">",
"      Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/78\">",
"      Cu-Uvin S, DeLong AK, Venkatesh KK, et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/79\">",
"      Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005; 19:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/80\">",
"      Moore AL, Kirk O, Johnson AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/81\">",
"      Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24:475.",
"     </a>",
"    </li>",
"    <li>",
"     Struble K, Soon G, Min M, et al. Meta-analysis of Efficacy Outcomes for Treatment-na&iuml;ve and Treatment-experienced HIV-infected Women in Randomized Controlled Clinical Trials: 2000 to 2008. 17th Conference on Retroviruses and Opportunistic Infections. February 16-19, 20010; San Francisco, California. Abstract 987b.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/83\">",
"      Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/84\">",
"      Collazos J, Asensi V, Cart&oacute;n JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007; 21:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/85\">",
"      Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/86\">",
"      Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/87\">",
"      Mazhude C, Jones S, Murad S, et al. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/88\">",
"      Gervasoni C, Ridolfo AL, Trifir&ograve; G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13:465.",
"     </a>",
"    </li>",
"    <li>",
"     Boxwell DE, Styrtt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors. ICAAC Sept 26-29 1999; Abstract 1284.",
"    </li>",
"    <li>",
"     DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     2002 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. file://aidsinfo.nih.gov/ContentFiles/OIpreventionGL.pdf (Accessed on March 30, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/92\">",
"      Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clin Care 1997; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/93\">",
"      Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010; 153:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/94\">",
"      Martin CP, Fain MJ, Klotz SA. The older HIV-positive adult: a critical review of the medical literature. Am J Med 2008; 121:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/95\">",
"      Katz MH, Cunningham WE, Fleishman JA, et al. Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Ann Intern Med 2001; 135:557.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsetc.org/aetc?page=cm-307_women (Accessed on November 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/97\">",
"      Aweeka FT, Rosenkranz SL, Segal Y, et al. The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS 2006; 20:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/98\">",
"      Stringer EM, Levy J, Sinkala M, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009; 23:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/99\">",
"      Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007; 197:144.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/100\">",
"      Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/101\">",
"      Richardson BA, Otieno PA, Mbori-Ngacha D, et al. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS 2007; 21:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/102\">",
"      Cejtin HE, Jacobson L, Springer G, et al. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS 2003; 17:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/103\">",
"      Baeten JM, Lavreys L, Overbaugh J. The influence of hormonal contraceptive use on HIV-1 transmission and disease progression. Clin Infect Dis 2007; 45:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/104\">",
"      de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/105\">",
"      Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; :CD003255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/106\">",
"      Fontanet AL, Saba J, Chandelying V, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS 1998; 12:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/107\">",
"      Cates W Jr, Stone KM. Family planning, sexually transmitted diseases and contraceptive choice: a literature update--Part I. Fam Plann Perspect 1992; 24:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/108\">",
"      Kelaghan J, Rubin GL, Ory HW, Layde PM. Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982; 248:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/35/16954/abstract/109\">",
"      Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol 2003; 101:797.",
"     </a>",
"    </li>",
"    <li>",
"     Public Health Service Task Force Recommendations for use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. www.AIDSInfo.nih.gov (Accessed on April 29, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3753 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16954=[""].join("\n");
var outline_f16_35_16954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30756391\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence of HIV in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for HIV acquisition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Depression and HIV disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACCESS TO QUALITY OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GENDER-RELATED BIOLOGICAL DIFFERENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Viral load differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS IN WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Candida vaginitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bacterial vaginosis, genital ulcers, and pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ABNORMAL CERVICAL CYTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cervical neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Effect of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      VULVAR AND PERIANAL PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MENSTRUAL ABNORMALITIES AND MENOPAUSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GENITAL TRACT SHEDDING OF HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PRIMARY CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HIV therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Health maintenance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CHOICE OF CONTRACEPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hormonal contraceptives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Effect on HIV disease progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Susceptibility to HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Intrauterine contraceptive device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Condoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Microbicides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      HIV AND PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30756391\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12538?source=related_link\">",
"      Approach to the patient with genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/28/10696?source=related_link\">",
"      Chancroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19192?source=related_link\">",
"      Disease associations of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/10/9386?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=related_link\">",
"      Screening for cervical cancer in HIV infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_35_16955="Outpatient care for VTE";
var content_f16_35_16955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Minimal requirements for early hospital discharge or outpatient therapy of venous thromboembolic disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        The responsible physician must ensure that all of the following conditions apply:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The patient is ambulatory and in stable condition, with normal vital signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is a low a priori risk of bleeding in the patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe renal insufficiency is not present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        There is a practical system in place for the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Administration of LMW heparin and/or warfarin with appropriate monitoring,",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Surveillance and treatment of recurrent VTE and bleeding complications",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VTE: venous thromboembolism; LMW heparin: low molecular weight heparin.",
"    </div>",
"    <div class=\"reference\">",
"     <br>",
"      Adapted from Hyers, TM, Agnelli, G, Hull, RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119:176S. (Sixth ACCP Consensus Conference on Antithrombotic Therapy).",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16955=[""].join("\n");
var outline_f16_35_16955=null;
var title_f16_35_16956="Vitamins lactation";
var content_f16_35_16956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended dietary allowances for vitamins during lactation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        RDA women",
"       </td>",
"       <td class=\"subtitle1\">",
"        Milk secretion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Efficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        CV",
"       </td>",
"       <td class=\"subtitle1\">",
"        RDA lactation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin C",
"       </td>",
"       <td>",
"        75 mg/d",
"       </td>",
"       <td>",
"        40 mg/d",
"       </td>",
"       <td>",
"        85 percent",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        120 mg/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiamine",
"       </td>",
"       <td>",
"        1.1 mg/d",
"       </td>",
"       <td>",
"        0.16 mg/d",
"       </td>",
"       <td>",
"        0.1 mg/d",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        1.4 mg/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Riboflavin",
"       </td>",
"       <td>",
"        1.1 mg/d",
"       </td>",
"       <td>",
"        0.3 mg/d",
"       </td>",
"       <td>",
"        0.1 mg/d",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        1.6 mg/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Niacin",
"       </td>",
"       <td>",
"        14 mg/d",
"       </td>",
"       <td>",
"        1.4 mg/d",
"       </td>",
"       <td>",
"        1 mg/d",
"       </td>",
"       <td>",
"        15 percent",
"       </td>",
"       <td>",
"        17 mg/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B6",
"       </td>",
"       <td>",
"        1.3 mg/d",
"       </td>",
"       <td>",
"        0.1 mg/d",
"       </td>",
"       <td>",
"        0.48 mg/d",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        2 mg/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folic acid",
"       </td>",
"       <td>",
"        400 &micro;g/d",
"       </td>",
"       <td>",
"        66&nbsp;&micro;g/d",
"       </td>",
"       <td>",
"        66&nbsp;&micro;g/d",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        500&nbsp;&micro;g/d",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B12",
"       </td>",
"       <td>",
"        2&nbsp;&micro;g/d",
"       </td>",
"       <td>",
"        0.33&nbsp;&micro;g/d",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        10 percent",
"       </td>",
"       <td>",
"        2.8&nbsp;&micro;g/d",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Dietary Reference Intakes. The Essential Guide to Nutrient Requirements. Otten, JJ, Hellwig, JP, Meyers, LD, eds. IoM, Washington, DC 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16956=[""].join("\n");
var outline_f16_35_16956=null;
var title_f16_35_16957="Irritant herbal ingredients";
var content_f16_35_16957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Irritant herbal ingredients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alfalfa",
"       </td>",
"       <td>",
"        Irritant, canavanine in seeds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arnica",
"       </td>",
"       <td>",
"        Irritant to mucous membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asafoetida",
"       </td>",
"       <td>",
"        Irritant gum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blue flag",
"       </td>",
"       <td>",
"        Irritant gum and oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bogbean",
"       </td>",
"       <td>",
"        Irritant to GI tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boldo",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buchu",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capsicum",
"       </td>",
"       <td>",
"        Capsaicinoids, mucosal irritants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cassia",
"       </td>",
"       <td>",
"        Irritant to mucous membranes, oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cinnamon",
"       </td>",
"       <td>",
"        Irritant to mucous membranes, oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cohosh, blue",
"       </td>",
"       <td>",
"        Irritant to mucous membranes; spasmogenic in vitro",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cowslip",
"       </td>",
"       <td>",
"        Irritant saponins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drosera",
"       </td>",
"       <td>",
"        Plubagin, irritant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eucalyptus",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        False unicorn",
"       </td>",
"       <td>",
"        Large doses may cause vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Figwort",
"       </td>",
"       <td>",
"        Purgative effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Garlic",
"       </td>",
"       <td>",
"        Raw clove",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ground ivy",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guaiacum",
"       </td>",
"       <td>",
"        Avoid if inflammatory condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Horse-chestnut",
"       </td>",
"       <td>",
"        Saponin constituents, contraindicated in existing renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Horseradish",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrangea",
"       </td>",
"       <td>",
"        May cause gastroenteritis, hydrangin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jamaica dogwood",
"       </td>",
"       <td>",
"        Irritant to humans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juniper",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lemon verbena",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lime flower",
"       </td>",
"       <td>",
"        Irritant to kidney, oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nettle",
"       </td>",
"       <td>",
"        Tea irritant to stomach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parsley",
"       </td>",
"       <td>",
"        Irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pennyroyal",
"       </td>",
"       <td>",
"        Toxic and irritant oil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pilewort",
"       </td>",
"       <td>",
"        Irritant sap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleurisy root",
"       </td>",
"       <td>",
"        Gastrointestinal irritant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pokeroot",
"       </td>",
"       <td>",
"        Irritant saponins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsatilla",
"       </td>",
"       <td>",
"        Irritant to mucous membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Queen's delight",
"       </td>",
"       <td>",
"        Diterpene constituents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarsaparilla",
"       </td>",
"       <td>",
"        Saponins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Senega",
"       </td>",
"       <td>",
"        Saponins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skunk cabbage",
"       </td>",
"       <td>",
"        Inflammatory and blistering to skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squill",
"       </td>",
"       <td>",
"        Saponins",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996, p.284.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16957=[""].join("\n");
var outline_f16_35_16957=null;
var title_f16_35_16958="LDL reduction and events";
var content_f16_35_16958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    LDL-cholesterol and coronary risk after pravastatin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the CARE trial of 4159 patients, therapy with pravastatin reduced the relative risk of the primary endpoint (coronary death or nonfatal myocardial infarction) at all serum LDL-cholesterol concentrations &ge;125 mg/dL (3.2 mmol/L). Lower LDL- cholesterol values were not associated with further benefit. The blue line represents the percentages of patients at each LDL concentration who were in the pravastatin group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Sacks, FM, Moye, LA, Davis, BR, et al, Circulation 1998; 97:1446",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16958=[""].join("\n");
var outline_f16_35_16958=null;
var title_f16_35_16959="Back leg raise video";
var content_f16_35_16959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1070px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PC/58435/Back_leg_raise_video.mp4?title=Back+leg+raise+video\" style=\"width:480px;height:336px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise video: Back leg raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise strengthens your buttocks and lower back. For an added challenge, you can modify the exercise to improve your balance.",
"    <br>",
"     <ol>",
"      <li>",
"       Stand behind a sturdy chair, holding on for balance. Breathe in slowly.",
"      </li>",
"      <li>",
"       Breathe out and slowly lift one leg straight back without bending your knee or pointing your toes. Try not to lean forward. The leg you are standing on should be slightly bent.",
"      </li>",
"      <li>",
"       Hold position for one second.",
"      </li>",
"      <li>",
"       Breathe in as you slowly lower your leg.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 times with other leg.",
"      </li>",
"      <li>",
"       Repeat 10 to 15 more times with each leg.",
"      </li>",
"     </ol>",
"     As you progress, you may want to add ankle weights.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_35_16959=[""].join("\n");
var outline_f16_35_16959=null;
